Collagen / peptide-based pharmaceutical composition and medical device containing said pharmaceutical composition

Abstract

The present invention is within the fields of medicinal chemistry, biotechnology, and medicine. The present invention provides compositions comprising one or more collagen mimetic peptides, optionally linked to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing, and diagnosing certain diseases and disorders in human and veterinary subjects, particularly anterior and posterior ocular diseases and disorders, periocular and extraocular diseases and disorders, and neurological or nervous system diseases and disorders, as well as methods of making such compositions. The present invention also provides medical devices comprising one or more of the compositions of the present invention. The present invention also provides methods of using the compositions and devices in the treatment and diagnosis of certain diseases and disorders in human and veterinary subjects, including anterior and posterior ocular diseases or disorders, periocular and extraocular diseases and disorders, and neurological or nervous system diseases or disorders.

Description

[Technical field]

[0001] STATEMENT REGARDING U.S. GOVERNMENT SPONSORED RESEARCH AND DEVELOPMENT Not applicable.

[0002] Names of the parties involved in the joint research agreement Not applicable.

[0003] REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY Not applicable.

[0004] The present invention is in the fields of medicinal chemistry, biotechnology, medicine and medical devices, and pharmaceutical compounds and medical devices for the treatment, prevention and amelioration of diseases, disorders and physical ailments in human and veterinary subjects. [Background technology]

[0005] Collagen is the most abundant protein in vertebrates, and is the basic structural protein of vertebrate tissues, present in virtually all tissues, including skin and other epithelial tissues (including the inner surface of most hollow organs, such as the hollow organs of the gastrointestinal tract), tendons, bones, blood vessels, cartilage, ligaments and teeth.In humans, collagen constitutes about one-third of total protein and about three-quarters of the dry weight of skin (see Shoulders, MD, and Raines, RT, Ann. Rev. Biochem. 78:929-958 (2009); Gelse, K., et al., Adv. Drug Deliv. Rev. 55:1531-1546 (2003)).

[0006] Collagen is a fibrous protein generally composed of a triple helix of two identical chains and a third chain that differs slightly in its chemical structure. Mammals produce at least 46 different collagen polypeptide chains that combine to form collagen variants or "types." To date, 28 collagen types have been described. Collagen types are generally grouped according to their structural morphology into fibrillar collagens (types I, II, III, V, and XI), which account for about 90% of all collagen proteins found in mammals, and nonfibrillar collagens (basement membrane or type IV, and other nonfibrillar collagen types with interrupted helical structures) (see references supra). The five most common collagen types and their tissue distribution are as follows:

[0007] Type I: skin, tendons, organs, bones, vascular connective tissue

[0008] Type II: cartilage

[0009] type III reticular connective tissue that often combines with type I collagen

[0010] Type IV: Basement membranes of epithelial tissues and certain solid tumors

[0011] Type V: Hair, placenta, outer cell membrane

[0012] In each of these variants, the collagen polypeptide chain is composed of about 300 repeats of the three amino acids proline (Pro), 4(R)-hydroxyproline (Hyp) and glycine (Gly), usually in the sequence XY-Gly, where X is often Pro and Y is often Hyp. In vertebrates, the typical repeat motif in collagen is ProProGly (see Hulmes, DJS, "Collagen Diversity, Synthesis and Assembly," in: Collagen: Structure and Mechanics, P. Fratzl, Ed., New York: Springer, pp. 15-47 (2008)). In vivo, the Pro residues are then enzymatically hydroxylated after collagen biosynthesis but before the chains begin to form triple helices. Thus, hydroxylation of at least one Pro residue in a ProProGly motif, typically forming ProHypGly, appears to be important for both proper folding and stability of the collagen triple helix, which is key to normal collagen structure and function in vivo (see Shoulders, MD, and Raines, RT, Ann. Rev. Biochem. 78:929-958 (2009)). For example, (ProHypGly) 10 The triple helix melting temperature of the (SEQ ID NO: 396) strand is 58° C., whereas the (ProProGly) 10 (SEQ ID NO: 397) The triple helix melting temperature of the strand is only 24° C. (Sakakibara et al., Biochim. Biophys. Acta, 303:198-202 (1973)), and (ProHypGly) 10 (SEQ ID NO: 396) The rate at which the chain folds into a triple helix is ​​(ProProGly) 10(SEQ ID NO: 397) chain (Chopra and Ananthanarayanan, Proc. Natl. Acad. Sci. USA, 79:7180-7184 (1982)).

[0013] Type I collagen is the most abundant and best studied collagen. In humans and most other animals, type I collagen forms more than 90% of the organic mass of bone and is the predominant collagen in tendons, skin, ligaments, cornea, and many interstitial connective tissues, including hyaline cartilage, brain, and the vitreous body, with a few exceptions. Collagen type I triple helices are usually formed as heterotrimers by two identical α1 chains and one α2 chain. In vivo, these triple helical fibers are primarily assembled into composite fibrils containing other collagen types, which vary depending on the type and location of the tissue, as described above (Fleischmajer, ED et al., J. Struct. Biol. 105: 162-169 (1990); Niyibizi, C. and Eyre, DR, Connect. Tissue Res. 20: 247-250 (1989)). In most organs, especially tendons and fascia, type I collagen provides tensile stiffness and in bone it determines the biomechanical properties of load-bearing capacity, tensile strength and torsional stiffness.

[0014] In connective tissues (e.g. bone, tendon, cartilage, ligament, skin, blood vessels, and teeth), individual collagen molecules are wound together in a dense triple helix. These helices are organized into fibrils with high tensile strength (Jones & Miller, J. Mol. Biol., 218:209-219 (1991)) by cross-linking individual triple-helical fibrils (Lodish, H. et al., "Collagen: The Fibrous Proteins of the Matrix", in: Molecular Cell Biology, 4th ed., Section 22.3, New York: WH Freeman (2000)). By varying the arrangement and cross-linking of collagen fibrils, vertebrates can support stresses in one (tendon), two (skin), or three (cartilage) dimensions.

[0015] Collagen plays a major role in maintaining the structural integrity of tissues and organs in the body. In all solid organs, collagen is the main component of the interstitial matrix and basement membrane, and in all connective tissues, especially bone and cartilage, collagen provides the main functional framework of the structure. However, collagen is also involved in various additional functions besides biomechanical aspects. For example, specific receptors on the cell surface and within the cell interact with collagen, and signaling by these receptors is involved in cell adhesion, cell differentiation, cell proliferation and other cell activities, and cell survival both in vivo and in vitro (Vogel, WF, Eur. J. Dermatol. 11: 506-514 (2001); Gelse, K., et al., Adv. Drug Deliv. Rev. 55:1531-1546 (2003)). Collagen is also involved in the uptake, local storage and delivery of growth factors and cytokines in various tissues where collagen is found. Through these receptor interactions, as well as storage and delivery functions, collagen plays an important role in organ development, wound healing and tissue repair (Chattopadhyay, S. and R. Raines, Biopolymers 101: 821-833 (2014); Yamaguchi, Y. et al., Nature 346: 281-284 (1990); Hay, ED, J. Cell Biol. 91:205s-223s (1981); Bautista, CM et al., Metabolism 39: 96-100 (1990); Zhu, Y. et al., J. Cell Biol. 144: 1069-1080 (1998); Schlegel, KA et al., Biomaterials 25:5387-5393 (2004); Kumar, VA, et al., Biomacromol. 15: 1484-1490 (2014).Due to these features, collagen has also been proposed as a potential transport vehicle for the delivery of therapeutic compounds (e.g., Chattopadhyay, S. et al., J. Tissue Eng. Regen. Med. 10:1012-1020 (2012); Schuppan, D. et al., Gastroenterol. 114: 139-152 (1998); Frenkel, SR et al., J. Bone Jt. Surg. 79-B: 831-836 (1997); Albu, MG et al., "Collagen-Based Drug Delivery Systems for Tissue Engineering", in: Biomaterials Applications for Nanomedicine, Pignatello, R. (Ed.), ISBN: 978-953-307-661-4, DOI: 10.5772 / 22981, Rijeka, Croatia: InTech, available from: https: / / www.intechopen.com / books / biomaterials-applications-for-nanomedicine / collagen-based-drug-delivery-systems-for-tissue-engineering (2011)) and for use in wound healing by directly promoting tissue repair or regeneration (Wakitani, S. et al., J. Bone Jt. Surg. 71-B: 74-80 (1989); Kumar, VA, et al., Biomacromol. 15: 1484-1490 (2014)). Collagen, particularly disrupted collagen, has also been implicated in tumor progression and metastasis in humans and other vertebrates (for an introductory review of this issue, see Fang, M., et al., Tumor Biol. 35:2871-2882 (2014)).

[0016] However, in addition to intact collagen molecules, collagen fragments also have potential therapeutic applications and may in fact perform better than native collagen. For example, non-collagenous fragments of collagens IV, XV and XVIII have been shown to promote vascular and tumor cell proliferation and affect a variety of other cellular activities (Ortega, N. and Werb, Z., J. Cell Sci. 115: 4201-4214 (2002); Davis, GE et al., Am. J. Pathol. 156: 1489-1498 (2000); O'Reilly, MS et al., Cell 88: 277-285 (1997)). Similarly, as described in more detail below, fragments of type I collagen or synthetic collagen pseudopeptides (CMPs) have recently been explored for their own properties and for their utility as active pharmaceutical ingredients (APIs) in the treatment of diseases and medical disorders for the delivery of skin wound healing agents (see U.S. Pat. Nos. 5,973,112, 7,122,521 and 7,858,741, and U.S. Patent Publication No. 2007 / 0275897A1, the disclosures of which are all incorporated by reference herein in their entireties; see also, e.g., Chattopadhyay, S. et al., J. Tissue Eng. Regen. Med. 10:1012-1020 (2012); Kumar, VA et al., Biomacromolecules 15:1484-1490 (2014)).

[0017] Collagen abnormalities are associated with a wide variety of human diseases, including eye diseases and disorders such as cataracts and glaucoma (Coudrillier, B., et al., PLoS ONE 10: e0131396 (2015); Huang, W. et al., Med.Sci. Monit. Basic Res. 19: 237-240 (2013); Dua, HS, et al., Br. J. Ophthalmol. 98: 691-697 (2014)), arthritis, rheumatism, osteoporosis, atherosclerosis, and liver cirrhosis. Collagen disruption is also associated with diseases in certain human and veterinary subjects, such as certain cancers, particularly carcinomas of hollow organs and certain sarcomas. See, e.g., Lauer, JL, and Fields, GB, "Collagen in Cancer", in The Tumor Microenvironment, New York: Springer, pp. 477-507 (2010). Collagen is also very useful in wound healing and is known to increase in areas of epithelial wounds undergoing healing, including the skin and the cornea of ​​the eye (see, e.g., U.S. Pat. Nos. 5,973,112 and 7,122,521, which are incorporated by reference in their entireties; see also Chattopadhyay, S., et al., J. Tissue Eng. Regen. Med. 10:1012-1020 (2012); Chattopadhyay, S., et al., Org. Biomol. Chem. 10:5892-5897 (2012); Kumar, VA, et al., Biomacromol. 15: 1484-1490 (2014)). Indeed, collagen, collagen fragments, or certain pseudo-peptides of native collagen have been reported to show promise in the treatment of certain wounds and diseases in humans and animals, particularly skin wounds (see, e.g., U.S. Pat. Nos. 5,973,112, 7,122,521, and 7,858,741, all of which are incorporated by reference in their entireties herein, and U.S. Patent Publication No. 2007 / 0275897 A1).See also Kumar, VA et al., Biomacromolecules 15:1484-1490 (2014). These collagen fragments or collagen pseudopeptides appear to specifically target collagen-disrupted areas associated with skin wounds by inserting into the disrupted collagen and modifying the native collagen I triple helix (see, e.g., Chattopadhyay, S., et al., J. Tissue Eng. Regen. Med. 10:1012-1020 (2012); Chattopadhyay, S., et al., Org. Biomol. Chem. 10:5892-5897 (2012)). As a result, attempts have been made to use collagen as a vehicle to deliver certain drugs with varying degrees of success (see, e.g., B. An, et al., Adv. Drug Deliv. Rev. 97:69-84 (2016); V. Chak, et al., Intl. J. Pharm. Teaching and Practices 4:811 (2013)). Collagen pseudopeptides have also been used topically to deliver conjugated therapeutic compounds, a neuropeptide known as substance P, to areas of skin wounds, and the CMP-substance P conjugates have been shown to accelerate wound healing in a mouse skin model (Chattopadhyay, S., et al., J. Tissue Eng. Regen. Med. 10:1012-1020 (2012)).Certain extracellular matrix (ECM) components, including collagen, are also involved in maintaining the proper structure and function of the nervous system, especially the peripheral nervous system, and disruption or damage of these ECM components often leads to neuronal impairment and / or death (e.g., Koopmans G, Hasse B, Sinis N. The role of collagen in peripheral nerve repair (Chapter 19). International Review of Neurobiology. Volume 87: Academic Press, Elsevier; pp. 363-79 (2009); Gao X, et al., Rev. Neurosci. 24(4):443-53 (2013); Campbell IC et al., J. Biomech. Eng. 136(2):021005 (2014); Vecino E et al., J. Cytol. Histol. S3:007 (2015); Vecino E., and Kwok, JCF, "The Extracellular Matrix in the Nervous System: The Good and the Bad Aspects", in Composition and Function of the Extracellular Matrix in the Human Body, F. Travascio, ed., Intech Open, ISBN 978-953-51-2416-0 (2016), accessed November 8, 2019, at http: / / dx.doi.org / 10.5772 / 62527).

[0018] Treatments for diseases / disorders can be expensive, difficult to deliver specifically, and can have deleterious effects at sites distant from the targeted site of action. For example, many pharmaceutical compositions, including antibiotics, small molecule therapeutics (e.g., anti-cancer compounds), and biologics (e.g., monoclonal antibody therapeutics), are administered parenterally in a non-targeted manner and must first diffuse or otherwise find their way to the affected site before they can exert their therapeutic effect. This "shotgun approach" to treatment necessarily requires larger doses, which can result in longer treatment periods and reduced patient compliance compared to therapeutic approaches that deliver therapeutic compounds and compositions in a more targeted manner that allows for controlled or programmable release at or near the affected site in human and veterinary subjects.

[0019] Thus, there is a need in the art for drug delivery systems, i.e. compositions and methods of use, that overcome many of these shortcomings in conventional treatments for certain diseases and disorders in human and veterinary subjects. Such advanced drug delivery systems would allow for the use of lower doses of pharmaceuticals and more targeted delivery of drugs to the intended site of action, as well as reducing treatment problems or delays due to non-compliance by patients. There is also a need for medical devices coated with the compositions that facilitate more rapid healing and recovery for humans and animals suffering from the diseases and disorders. Finally, there is a need in the art for methods of manufacturing the compositions and medical devices that meet the needs of the medical and patient communities to maximize therapeutic efficacy while controlling costs. Summary of the Invention

[0020] The inventors have concluded that because collagen destruction is associated with various diseases and disorders in humans and other animals, conjugating various therapeutic and / or diagnostic compounds with collagen or collagen mimetic peptides provides a simple, rapid and reproducible means of overcoming many of the above limitations in drug delivery.The present invention therefore provides such a drug delivery system, medical device and method of manufacture thereof.The present invention thus meets the above needs in the art.

[0021] In one aspect, the invention provides compositions comprising one or more collagen mimetic peptides (CMPs), which in certain embodiments are conjugated with one or more therapeutic compounds and / or one or more diagnostic compounds to form CMP conjugates and compositions. The CMPs and CMP conjugates, and compositions comprising the CMPs and / or CMP conjugates, are useful for the treatment, prevention, amelioration and diagnosis of various diseases, disorders and physical conditions in human and veterinary subjects. In certain embodiments of this aspect, the invention provides compositions comprising the CMPs and / or CMP conjugates, and one or more pharma- ceutical acceptable carriers, excipients or compounding agents, and optionally one or more additional therapeutic or diagnostic agents, to provide therapeutic and diagnostic compositions useful for the treatment, prevention, amelioration or diagnosis of certain diseases and disorders in human and veterinary subjects.

[0022] In another aspect, the invention provides methods of treating, preventing, ameliorating or diagnosing certain diseases and disorders in human and veterinary subjects by administering the conjugates and / or compositions of the invention to a human or veterinary subject suffering from or susceptible to the disease or disorder. Diseases and disorders that are suitably treated, prevented, cured, ameliorated or diagnosed by this aspect of the invention include eye diseases or disorders, skin diseases or disorders, cancer, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases or disorders, cardiovascular diseases or disorders, bone diseases or disorders, and rheumatic diseases or disorders.

[0023] In yet another aspect, the invention provides a medical device coated with or containing one or more of the conjugates or compositions of the invention. In a related aspect, the invention provides a method of treating, curing, preventing or ameliorating a disease or disorder in a human or veterinary subject comprising implanting one or more of the medical devices of this aspect of the invention into the human or veterinary subject under conditions such that the disease or disorder is treated, cured, prevented or ameliorated.

[0024] In yet another aspect, the present invention provides methods of producing the compositions, conjugates, and medical devices of the present invention.

[0025] Other objects, advantages and features of the present invention will become readily apparent to those skilled in the art from a consideration of the description, drawings, examples and claims provided herein. [Brief description of the drawings]

[0026] [Figure 1] 1 is a series of photomicrographs showing the healing of corneal wounds in mouse eyes at 0 and 16 hours post-wounding upon treatment with certain compositions of the invention. Wounds were introduced into the corneas of mice, and the mice were immediately treated with vehicle (PBS, Figures 1a and 1e), 100 ng / mL epidermal growth factor (EGF, Figures 1b and 1f), or 25 nM (approximately 3 mg / kg) of (Pro-Pro-Gly)7CMP (SEQ ID NO: 1) of the invention ("Compound 3," Figures 1c and 1g) or (Hyp-Pro-Gly)7-SubP CMP-TC (SEQ ID NO: 391) of the invention ("Compound 10," Figures 1d and 1h). Residual corneal abrasions and damage to the lower corneal stroma were then revealed by fluorescein staining and fluorescence photomicrography of the eyes at 0 hours (Figures 1a-1d) and 16 hours (Figures 1e-1h) post-wounding. Figures 1i and 1j are photomicrographs of H&E stained thin sections of corneal epithelium and subepithelium 24 hours after wounding, treated with PBS (Figure 1i) or Compound 3 (Figure 1j).

[0027] [Diagram 2] 2A and 2B are high magnification photomicrographs of H&E stained sections of the corneal epithelium of Figures 1i and 1j above. Figure 2a shows a PBS treated section, and Figure 2b shows a Compound 3 treated section. Arrows indicate the absence (Figure 2a) or presence (Figure 2b) of basement membrane.

[0028] [Diagram 3] 1 is a bar graph of epithelial layer adhesion length in wounded corneal tissue treated with PBS, EGF, Compound 3 or Compound 10 compared to unwounded (intact) corneas. Error bars are the mean ± SEM (n=3).

[0029] [Figure 4] Phase contrast micrographs of retinal pigment epithelial (RPE) cells seeded on collagen-coated and collagenase-treated tissue culture plates that were incubated overnight after seeding. Following collagenase treatment, plates were treated with vehicle (PBS, Figure 4a) or compound 3 (Figure 4b) prior to seeding the cells.

[0030] [Diagram 5] High magnification DIC micrographs of collagen-coated and collagenase-treated plates from the experiment shown in Figure 4. Figure 5a shows a vehicle-treated plate and Figure 5b shows a plate treated with Compound 3.

[0031] [Figure 6] FIG. 5 is a bar graph showing the degree of parallel (i.e. unidirectional) orientation of collagen observed in the collagen-coated and collagenase-treated plates of FIGS. 4 and 5 treated with PBS (vehicle) or compound 3, as quantified using digital analysis of the photomicrographs shown in FIG. 5 and below the bar graph.

[0032] [Figure 7] 7A-7B are bar graphs (and corresponding photomicrographs) of the number of RPE cell nuclei per unit area of ​​cells seeded onto culture plates treated with vehicle (PBS, FIG. 7A) or compound 3 (FIG. 7B).

[0033] [Figure 8] Series of micrographs of the underside of crystal violet-stained tissue culture membrane inserts coated with vehicle (water, Figure 8a), native type I collagen (Figure 8b) or compound 3 (Figure 8c), onto whose apical side RPE cells were seeded and allowed to migrate for 24 h.

[0034] [Figure 9] 9 is a bar graph of the number of cells that migrate to and adhere to the underside of the membrane of FIG. 8, as determined by counting cells by microscopy in 10x and 20x magnification fields, with 6 fields per membrane insert.

[0035] [Figure 10] 10 is a bar graph showing a repeat of the experiment shown in Figures 8 and 9, except that only the apical surface of the transwell membrane was coated with vehicle, native human collagen type I or Compound 3. Cells were then plated, incubated, allowed to migrate and quantified as shown in Figure 9.

[0036] [Figure 11] Figure 11A shows the cleavage of type I collagen by matrix metalloproteinase 1 (MMP-1) in an in vitro assay. Figure 11A shows stain-attenuated SDS-PAGE of untreated human type I atelocollagen ("collagen" lane) or human type I atelocollagen treated with MMP-1 ("cleaved collagen" lane). TCA is the 3 / 4 fragment of α1(I) collagen, and TCB is the 1 / 4 fragment of α2(I) collagen. Arrows indicate the α1(I) and α2(I) bands quantified in Figure 11B. Figure 11B is a bar graph showing the quantification of full-length α1(I) and α2(I) bands in untreated collagen compared to collagen cleaved by MMP-1.

[0037] [Figure 12]12A-12D). Following coating, plates were treated with vehicle (PBS, FIGS. 12A and 12B) or CMP A (SEQ ID NO:3) (FIG. 12C) or CMP B (SEQ ID NO:6) (FIG. 12D) prior to seeding the cells. Cells were incubated at 37° C. for 19 h prior to photomicrography.

[0038] [Figure 13] 13A-B are bar graphs of the amount of cell adhesion of RPE cells observed under various conditions described in FIG. 12, including treatment with CMP A (SEQ ID NO:3), B (SEQ ID NO:6), C (SEQ ID NO:391) or D (SEQ ID NO:13). All data were normalized to adhesion observed in the "cut collagen" replicates. *, p≦0.005 vs. cut collagen. In FIG. 13A, all samples are shown, and FIG. 13B is a scaled version of the data shown in FIG. 13A, excluding the "collagen" data for clarity. Error bars are the mean ± SEM (n=3).

[0039] [Figure 14]A series of inverted brightfield micrographs of dorsal root ganglion (DRG) neurons plated onto tissue culture plates coated overnight with collagen type I ("Collagen", FIG. 14A) or MMP-1 digested collagen type I ("Cleaved Collagen", FIG. 14B-14F). Following coating, plates were treated with vehicle (PBS, FIG. 14A and 14B) or CMP A (SEQ ID NO:3) (FIG. 14C), CMP B (SEQ ID NO:6) (FIG. 14D), CMP C (SEQ ID NO:391) (FIG. 14E) or CMP D (SEQ ID NO:13) (FIG. 14F) prior to seeding the cells. Cells were incubated at 37° C. for 48 hours prior to photomicrography for 19 hours.

[0040] [Figure 15] 15A-B are bar graphs of the size of dendritic outgrowths ("Dendritic Field Area", FIG. 15A) and the length of the longest neurite in DRG neurons observed under various conditions described in FIG. 14, including treatment with CMP A (SEQ ID NO:3), B (SEQ ID NO:6), C (SEQ ID NO:391) or D (SEQ ID NO:13). All data were normalized to adhesions observed in the "cut collagen" replicates. * in FIG. 15A, p≦0.03 vs. cut collagen; * in FIG. 15B, p≦0.02 vs. cut collagen. Error bars are mean±sem (n=3).

[0041] [Figure 16]16A and 16B) or ocular surface instillation (FIGS. 16C and 16D) of a solution of (Pro-Pro-Gly)7 (SEQ ID NO: 1) CMP conjugated to Tide Fluor™2 ("TF2-CMP"). Mice were sacrificed 3 days after surface application of TF2-CMP or on the same day as intravitreal injection, and the location of TF2-CMP was measured. FIGS. 16A and 16C show the location of TF2-CMP outside the nuclei of the ganglion cell layer of the retina (arrows indicate retinal blood vessels and arrowheads indicate ganglion cell nuclei), while FIGS. 16B and 16D show the location of TF2-CMP in or near the inner limiting membrane (vitreous surface) of the retina. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0042] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below.

[0043] According to a first aspect, the present invention provides a composition suitable for use in medicine to treat or prevent a disease, disorder, structural abnormality or injury in a human or veterinary subject in need of such treatment or prevention. In a particular embodiment, the composition provided by the present invention comprises (a) at least one collagen pseudopeptide (CMP) linked to at least one additional therapeutic compound (TC) to form a CMP-TC conjugate, and (b) one or more pharmacologic suitable carriers. In a related aspect, the present invention provides a composition suitable for use in a diagnostic suitable for diagnosing or detecting a disease, disorder, structural abnormality or injury in a human or veterinary subject in need of such diagnosis or detection. In a particular embodiment, the composition provided by the present invention comprises (a) at least one collagen pseudopeptide (CMP) linked to at least one diagnostic compound or agent (DC) to form a CMP-DC conjugate, and (b) one or more pharmacologic suitable carriers. In other related embodiments, the present invention provides compositions comprising (a) at least one collagen pseudopeptide (CMP) and (b) at least one additional therapeutic compound, where the CMP and the at least one additional therapeutic compound are mixed or "co-formulated" in a combination formulation, optionally with one or more pharma- ceutical suitable carriers. In a similar embodiment, the present invention provides compositions comprising (a) at least one collagen pseudopeptide (CMP) and (b) at least one diagnostic compound or agent, such as a labeling compound or agent, where the CMP and the at least one diagnostic compound or agent are mixed or "co-formulated" in a combination formulation, optionally with one or more pharma-ceutical suitable carriers, for use in one or more diagnostic methods of the present invention.

[0044] In a particular embodiment of the invention, the collagen pseudopeptide has the sequence (Xaa-Yaa-Gly). n(SEQ ID NO:398), wherein Xaa is independently selected from the group consisting of proline, 4S-hydroxyproline, fluoroproline, chloroproline, lysine, cysteine ​​and methionine, Yaa is independently selected from the group consisting of proline, 4R-hydroxyproline, fluoroproline, chloroproline, lysine, cysteine ​​and methionine, Gly is a glycine residue, and n is an integer ranging from 1 to 20, e.g., 3 to 15, 5 to 15, or 5 to 10, preferably 5, 6, 7, 8, 9 or 10.

[0045] In certain embodiments of the invention, the collagen pseudo-peptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer or an amino acid sequence corresponding to said 21-mer comprising seven repeats of the proline-proline-glycine triamino acid sequence ((Pro-Pro-Gly)7), i.e., Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Gly-Pro-Gly-Pro-Gly (SEQ ID NO:1).

[0046] In certain other embodiments of the invention, the collagen pseudo-peptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer containing seven repeats of hydroxyproline (Hyp), preferably a three amino acid sequence in which the 4S-hydroxyproline residue replaces Proline 1 of SEQ ID NO:1 to give an amino acid sequence of 7 repeats of 4S-hydroxyproline-proline-glycine ((Hyp-Pro-Gly)7), i.e., Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:2), or an amino acid sequence corresponding to said 21-mer.

[0047] In certain other embodiments of the invention, the collagen pseudo-peptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer or an amino acid sequence corresponding to said 21-mer, comprising seven repeats of the three amino acid sequence Hyp, preferably wherein the 4S-hydroxyproline residue replaces Proline 2 of SEQ ID NO:1 to give an amino acid sequence of 7 repeats of 4S-hydroxyproline-proline-glycine ((Pro-Hyp-Gly)7), i.e., Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:3).

[0048] In certain other embodiments of the invention, the collagen pseudo-peptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer containing seven repeats of a three amino acid sequence in which fluoroproline (Flp) replaces proline 1 of SEQ ID NO:1 to give an amino acid sequence of fluoroproline-proline-glycine heptad repeats ((Flp-Pro-Gly)7), i.e., Flp-Pro-Gly-Flp-Pro-Gly-Flp-Pro-Gly-Flp-Pro-Gly-Flp-Pro-Gly-Flp-Pro-Gly-Flp-Pro-Gly (SEQ ID NO:4), or an amino acid sequence corresponding to said 21-mer.

[0049] In certain other embodiments of the invention, the collagen pseudopeptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer containing seven repeats of a three amino acid sequence in which Flp replaces Proline 2 of SEQ ID NO:1 to give the amino acid sequence of Proline-Fluoroproline-Glycine ((Pro-Flp-Gly)7), i.e., Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:5), or an amino acid sequence corresponding to said 21-mer.

[0050] In certain other embodiments of the invention, the collagen pseudo-peptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer containing seven repeats of a three amino acid sequence in which fluoroproline (Flp) replaces proline 1 of SEQ ID NO:1 and Hyp replaces proline 2 of SEQ ID NO:1, giving an amino acid sequence of fluoroproline-hydroxyproline-glycine heptad repeats ((Flp-Hyp-Gly)7), i.e., Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:6).

[0051] In CMPs that contain Flp, the Flp portion may be in the 4-cis or 4-trans configuration, preferably in the 4-cis configuration.

[0052] In certain other embodiments of the invention, the collagen pseudo-peptide may comprise, consist of, or have an amino acid sequence that is, or corresponds to, a 21-mer containing seven repeats of a three amino acid sequence in which chloroproline (Clp) replaces proline 1 of SEQ ID NO:1 to give the amino acid sequence of chloroproline-proline-glycine heptad repeats ((Clp-Pro-Gly)7), i.e., Clp-Pro-Gly-Clp-Pro-Gly-Clp-Pro-Gly-Clp-Pro-Gly-Clp-Pro-Gly-Clp-Pro-Gly-Clp-Pro-Gly (SEQ ID NO:7).

[0053] In certain other embodiments of the invention, the collagen pseudo-peptide may comprise, consist of, or have an amino acid sequence that is, or corresponds to, a 21-mer containing seven repeats of a three amino acid sequence in which chloroproline (Clp) replaces proline 2 of SEQ ID NO:1 to give the amino acid sequence of proline-chloroproline-glycine heptad repeats ((Pro-Clp-Gly)7), i.e., Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:8).

[0054] In certain other embodiments of the invention, the collagen pseudopeptide comprises, consists essentially of, or consists of an amino acid sequence that is a 21-mer containing seven repeats of a three amino acid sequence in which Clp replaces Proline 1 of SEQ ID NO:1 and Hyp replaces Proline 2 of SEQ ID NO:1 to give an amino acid sequence of chloroproline-hydroxyproline-glycine heptad repeats ((Clp-Hyp-Gly)7), i.e., Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:9).

[0055] In CMPs that contain Clp, the Clp moiety may be in the 4-cis or 4-trans configuration, preferably in the 4-cis configuration.

[0056] In certain other embodiments of the invention, the collagen pseudo-peptide may comprise, consist of, or have an amino acid sequence that is, or corresponds to, a 21-mer of any one of SEQ ID NOs:1-9, in which at least one cysteine ​​(Cys) residue is replaced with at least one proline residue of SEQ ID NO:1, at least one hydroxyproline residue of SEQ ID NOs:2-3, 6, at least one fluoroproline residue of SEQ ID NOs:4-6, or at least one chloroproline residue of SEQ ID NOs:7-9, giving, for example, the following sequence:

[0057] Pro-Pro-Gly-Pro-Pro-Gly-Cys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:10);

[0058] Hyp-Pro-Gly-Hyp-Pro-Gly-Cys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:11);

[0059] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Cys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:12);

[0060] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:13);

[0061] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:14);

[0062] Cys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:15);

[0063] Pro-Cys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:16);

[0064] Pro-Pro-Gly-Cys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:17);

[0065] Pro-Pro-Gly-Pro-Cys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:18);

[0066] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Cys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:19);

[0067] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Cys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:20);

[0068] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Cys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:21);

[0069] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Cys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:22);

[0070] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Cys-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:23);

[0071] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Cys-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:24);

[0072] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Cys-Gly-Cys-Pro-Gly (SEQ ID NO:25);

[0073] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Cys-Pro-Gly (SEQ ID NO:26);

[0074] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Cys-Gly (SEQ ID NO:27);

[0075] Cys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:28);

[0076] Hyp-Cys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:29);

[0077] Hyp-Pro-Gly-Cys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:30);

[0078] Hyp-Pro-Gly-Hyp-Cys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:31);

[0079] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Cys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:32);

[0080] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Cys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO: 33);

[0081] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Cys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:34);

[0082] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Cys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:35);

[0083] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Cys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:36);

[0084] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Cys-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:37);

[0085] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Cys-Gly-Hyp-Pro-Gly (SEQ ID NO:38);

[0086] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Cys-Pro-Gly (SEQ ID NO:39);

[0087] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Cys-Gly (SEQ ID NO:40);

[0088] Cys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:41);

[0089] Pro-Cys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:42);

[0090] Pro-Hyp-Gly-Cys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:43);

[0091] Pro-Hyp-Gly-Pro-Cys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:44);

[0092] Pro-Hyp-Gly-Pro-Hyp-Gly-Cys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:45);

[0093] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Cys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:46);

[0094] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Cys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:47);

[0095] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Cys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:48);

[0096] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Cys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:49);

[0097] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Cys-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:50);

[0098] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Cys-Gly-Pro-Hyp-Gly (SEQ ID NO:51);

[0099] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Cys-Hyp-Gly (SEQ ID NO:52);

[0100] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Cys-Gly (SEQ ID NO:53);

[0101] Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:54);

[0102] Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:55);

[0103] Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:56);

[0104] Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:57);

[0105] Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:58);

[0106] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:59);

[0107] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:60);

[0108] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:61);

[0109] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:62);

[0110] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:63);

[0111] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly (SEQ ID NO:64);

[0112] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly (SEQ ID NO:65);

[0113] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly (SEQ ID NO:66);

[0114] Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:67);

[0115] Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:68);

[0116] Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:69);

[0117] Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:70);

[0118] Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:71);

[0119] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:72);

[0120] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:73);

[0121] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:74);

[0122] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:75);

[0123] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:76);

[0124] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:77);

[0125] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly-Pro-Flp-Gly (SEQ ID NO:78);

[0126] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Cys-Flp-Gly (SEQ ID NO:79);

[0127] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Cys-Gly (SEQ ID NO:80);

[0128] Cys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:81);

[0129] Flp-Cys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:82);

[0130] Flp-Hyp-Gly-Cys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:83);

[0131] Flp-Hyp-Gly-Flp-Cys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:84);

[0132] Flp-Hyp-Gly-Flp-Hyp-Gly-Cys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:85);

[0133] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Cys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:86);

[0134] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Cys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:87);

[0135] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Cys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:88);

[0136] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Cys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:89);

[0137] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Cys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:90);

[0138] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Cys-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:91);

[0139] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Cys-Gly-Flp-Hyp-Gly (SEQ ID NO:92);

[0140] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Cys-Hyp-Gly (SEQ ID NO:93);

[0141] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Cys-Gly (SEQ ID NO:94);

[0142] Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:95);

[0143] Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:96);

[0144] Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:97);

[0145] Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:98);

[0146] Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:99);

[0147] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:100);

[0148] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:101);

[0149] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:102);

[0150] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:103);

[0151] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:104);

[0152] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly (SEQ ID NO:105);

[0153] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly (SEQ ID NO:106);

[0154] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly (SEQ ID NO:107);

[0155] Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:108);

[0156] Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:109);

[0157] Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:110);

[0158] Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:111);

[0159] Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:112);

[0160] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:113);

[0161] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:114);

[0162] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:115);

[0163] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:116);

[0164] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:117);

[0165] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:118);

[0166] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly-Pro-Clp-Gly (SEQ ID NO:119);

[0167] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Cys-Clp-Gly (SEQ ID NO:120);

[0168] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Cys-Gly (SEQ ID NO:121);

[0169] Cys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:122);

[0170] Clp-Cys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:123);

[0171] Clp-Hyp-Gly-Cys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:124);

[0172] Clp-Hyp-Gly-Clp-Cys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:125);

[0173] Clp-Hyp-Gly-Clp-Hyp-Gly-Cys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:126);

[0174] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Cys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:127);

[0175] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Cys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:128);

[0176] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Cys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:129);

[0177] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Cys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:130);

[0178] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Cys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:131);

[0179] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Cys-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:132);

[0180] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Cys-Gly-Clp-Hyp-Gly (SEQ ID NO:133);

[0181] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Cys-Hyp-Gly (SEQ ID NO:134);および

[0182] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Cys-Gly(SEQ ID NO:135)。

[0183] In certain other embodiments of the invention, the collagen pseudo-peptide may comprise, consist of, or have an amino acid sequence that is, or corresponds to, a 21-mer of any one of SEQ ID NOs:1-9, in which at least one methionine (Met) residue is replaced by at least one proline residue of SEQ ID NO:1, at least one hydroxyproline residue of SEQ ID NOs:2-3, 6, at least one fluoroproline residue of SEQ ID NOs:4-6, or at least one chloroproline residue of SEQ ID NOs:7-9, giving, for example, the following sequence:

[0184] Pro-Pro-Gly-Pro-Pro-Gly-Met-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:136);

[0185] Hyp-Pro-Gly-Hyp-Pro-Gly-Met-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:137);

[0186] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Met-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:138);

[0187] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:139);

[0188] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:140);

[0189] Met-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:141);

[0190] Pro-Met-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:142);

[0191] Pro-Pro-Gly-Met-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:143);

[0192] Pro-Pro-Gly-Pro-Met-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:144);

[0193] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Met-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:145);

[0194] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Met-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:146);

[0195] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Met-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:147);

[0196] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Met-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:148);

[0197] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Met-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:149);

[0198] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Met-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:150);

[0199] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Met-Gly-Pro-Pro-Gly (SEQ ID NO:151);

[0200] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Met-Pro-Gly (SEQ ID NO:152);

[0201] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Met-Gly (SEQ ID NO:153);

[0202] Met-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:154);

[0203] Hyp-Met-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:155);

[0204] Hyp-Pro-Gly-Met-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:156);

[0205] Hyp-Pro-Gly-Hyp-Met-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:157);

[0206] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Met-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:158);

[0207] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Met-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:159);

[0208] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Met-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:160);

[0209] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Met-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:161);

[0210] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Met-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:162);

[0211] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Met-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:163);

[0212] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Met-Gly-Hyp-Pro-Gly (SEQ ID NO:164);

[0213] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Met-Pro-Gly (SEQ ID NO:165);

[0214] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Met-Gly (SEQ ID NO:166);

[0215] Met-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:167);

[0216] Pro-Met-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:168);

[0217] Pro-Hyp-Gly-Met-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:169);

[0218] Pro-Hyp-Gly-Pro-Met-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:170);

[0219] Pro-Hyp-Gly-Pro-Hyp-Gly-Met-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:171);

[0220] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Met-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:172);

[0221] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Met-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:173);

[0222] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Met-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:174);

[0223] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Met-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:175);

[0224] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Met-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:176);

[0225] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Met-Gly-Pro-Hyp-Gly (SEQ ID NO:177);

[0226] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Met-Hyp-Gly (SEQ ID NO:178);

[0227] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Met-Gly (SEQ ID NO:179);

[0228] Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:180);

[0229] Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:181);

[0230] Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:182);

[0231] Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:183);

[0232] Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:184);

[0233] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:185);

[0234] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:186);

[0235] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:187);

[0236] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:188);

[0237] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:189);

[0238] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly (SEQ ID NO:190);

[0239] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly (SEQ ID NO:191);

[0240] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly (SEQ ID NO:192);

[0241] Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:193);

[0242] Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:194);

[0243] Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:195);

[0244] Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:196);

[0245] Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:197);

[0246] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:198);

[0247] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:199);

[0248] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:200);

[0249] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:201);

[0250] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:202);

[0251] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:203);

[0252] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly-Pro-Flp-Gly (SEQ ID NO:204);

[0253] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Met-Flp-Gly (SEQ ID NO:205);

[0254] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Met-Gly (SEQ ID NO:206);

[0255] Met-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:207);

[0256] Flp-Met-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:208);

[0257] Flp-Hyp-Gly-Met-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:209);

[0258] Flp-Hyp-Gly-Flp-Met-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:210);

[0259] Flp-Hyp-Gly-Flp-Hyp-Gly-Met-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:211);

[0260] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Met-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:212);

[0261] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Met-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:213);

[0262] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Met-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:214);

[0263] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Met-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:215);

[0264] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Met-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:216);

[0265] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Met-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:217);

[0266] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Met-Gly-Flp-Hyp-Gly (SEQ ID NO:218);

[0267] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Met-Hyp-Gly (SEQ ID NO:219);

[0268] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Met-Gly (SEQ ID NO:220);

[0269] Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:221);

[0270] Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:222);

[0271] Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:223);

[0272] Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:224);

[0273] Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:225);

[0274] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:226);

[0275] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:227);

[0276] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:228);

[0277] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:229);

[0278] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:230);

[0279] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly (SEQ ID NO:231);

[0280] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly (SEQ ID NO:232);

[0281] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly (SEQ ID NO:233);

[0282] Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:234);

[0283] Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:235);

[0284] Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:236);

[0285] Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:237);

[0286] Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:238);

[0287] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:239);

[0288] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:240);

[0289] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:241);

[0290] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:242);

[0291] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:243);

[0292] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:244);

[0293] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly-Pro-Clp-Gly (SEQ ID NO:245);

[0294] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Met-Clp-Gly (SEQ ID NO:246);

[0295] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Met-Gly (SEQ ID NO:247);

[0296] Met-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:248);

[0297] Clp-Met-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:249);

[0298] Clp-Hyp-Gly-Met-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:250);

[0299] Clp-Hyp-Gly-Clp-Met-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:251);

[0300] Clp-Hyp-Gly-Clp-Hyp-Gly-Met-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:252);

[0301] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Met-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:253);

[0302] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Met-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:254);

[0303] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Met-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:255);

[0304] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Met-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:256);

[0305] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Met-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:257);

[0306] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Met-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:258);

[0307] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Met-Gly-Clp-Hyp-Gly (SEQ ID NO:259);

[0308] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Met-Hyp-Gly (SEQ ID NO:260); and

[0309] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Met-Gly (SEQ ID NO:261).

[0310] In certain other embodiments of the invention, the collagen pseudo-peptide may comprise, consist of, or have an amino acid sequence that is, or corresponds to, a 21-mer of any one of SEQ ID NOs:1-9, in which at least one lysine (Lys) residue is replaced with at least one proline residue of SEQ ID NO:1, at least one hydroxyproline residue of SEQ ID NOs:2-3, 6, at least one fluoroproline residue of SEQ ID NOs:4-6, or at least one chloroproline residue of SEQ ID NOs:7-9, giving, for example, the following sequence:

[0311] Pro-Pro-Gly-Pro-Pro-Gly-Lys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:262);

[0312] Hyp-Pro-Gly-Hyp-Pro-Gly-Lys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:263);

[0313] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Lys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:264);

[0314] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:265);

[0315] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:266);

[0316] Lys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:267);

[0317] Pro-Lys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:268);

[0318] Pro-Pro-Gly-Lys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:269);

[0319] Pro-Pro-Gly-Pro-Lys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:270);

[0320] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Lys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:271);

[0321] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Lys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:272);

[0322] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Lys-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:273);

[0323] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Lys-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:274);

[0324] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Lys-Gly-Pro-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:275);

[0325] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Lys-Pro-Gly-Pro-Pro-Gly (SEQ ID NO:276);

[0326] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Lys-Gly-Pro-Pro-Gly (SEQ ID NO:277);

[0327] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Lys-Pro-Gly (SEQ ID NO:278);

[0328] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Lys-Gly (SEQ ID NO:279);

[0329] Lys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:280);

[0330] Hyp-Lys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:281);

[0331] Hyp-Pro-Gly-Lys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:282);

[0332] Hyp-Pro-Gly-Hyp-Lys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:283);

[0333] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Lys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:284);

[0334] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Lys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:285);

[0335] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Lys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:286);

[0336] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Lys-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:287);

[0337] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Lys-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:288);

[0338] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Lys-Pro-Gly-Hyp-Pro-Gly (SEQ ID NO:289);

[0339] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Lys-Gly-Hyp-Pro-Gly (SEQ ID NO:290);

[0340] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Lys-Pro-Gly (SEQ ID NO:291);

[0341] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Lys-Gly (SEQ ID NO:292);

[0342] Lys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:293);

[0343] Pro-Lys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:294);

[0344] Pro-Hyp-Gly-Lys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:295);

[0345] Pro-Hyp-Gly-Pro-Lys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:296);

[0346] Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:297);

[0347] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:298);

[0348] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Lys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:299);

[0349] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:300);

[0350] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Lys-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:301);

[0351] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Hyp-Gly-Pro-Hyp-Gly (SEQ ID NO:302);

[0352] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Lys-Gly-Pro-Hyp-Gly (SEQ ID NO:303);

[0353] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Hyp-Gly (SEQ ID NO:304);

[0354] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Lys-Gly (SEQ ID NO:305);

[0355] Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:306);

[0356] Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:307);

[0357] Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:308);

[0358] Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:309);

[0359] Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:310);

[0360] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:311);

[0361] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:312);

[0362] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:313);

[0363] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:314);

[0364] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:315);

[0365] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly (SEQ ID NO:316);

[0366] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly (SEQ ID NO:317);

[0367] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly (SEQ ID NO:318);

[0368] Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:319);

[0369] Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:320);

[0370] Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:321);

[0371] Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:322);

[0372] Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:323);

[0373] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:324);

[0374] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:325);

[0375] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:326);

[0376] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:327);

[0377] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:328);

[0378] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly-Pro-Flp-Gly (SEQ ID NO:329);

[0379] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly-Pro-Flp-Gly (SEQ ID NO:330);

[0380] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Lys-Flp-Gly (SEQ ID NO:331);

[0381] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Lys-Gly (SEQ ID NO:332);

[0382] Lys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:333);

[0383] Flp-Lys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:334);

[0384] Flp-Hyp-Gly-Lys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:335);

[0385] Flp-Hyp-Gly-Flp-Lys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:336);

[0386] Flp-Hyp-Gly-Flp-Hyp-Gly-Lys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:337);

[0387] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Lys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:338);

[0388] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Lys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:339);

[0389] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Lys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:340);

[0390] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Lys-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:341);

[0391] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Lys-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:342);

[0392] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Lys-Hyp-Gly-Flp-Hyp-Gly (SEQ ID NO:343);

[0393] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Lys-Gly-Flp-Hyp-Gly (SEQ ID NO:344);

[0394] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Lys-Hyp-Gly (SEQ ID NO:345);

[0395] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Lys-Gly (SEQ ID NO:346);

[0396] Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:347);

[0397] Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:348);

[0398] Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:349);

[0399] Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:350);

[0400] Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:351);

[0401] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:352);

[0402] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:353);

[0403] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:354);

[0404] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:355);

[0405] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:356);

[0406] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly (SEQ ID NO:357);

[0407] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly (SEQ ID NO:358);

[0408] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly (SEQ ID NO:359);

[0409] Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:360);

[0410] Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:361);

[0411] Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:362);

[0412] Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:363);

[0413] Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:364);

[0414] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:365);

[0415] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:366);

[0416] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:367);

[0417] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:368);

[0418] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:369);

[0419] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly-Pro-Clp-Gly (SEQ ID NO:370);

[0420] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly-Pro-Clp-Gly (SEQ ID NO:371);

[0421] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Lys-Clp-Gly (SEQ ID NO:372);

[0422] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Lys-Gly (SEQ ID NO:373);

[0423] Lys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:374);

[0424] Clp-Lys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:375);

[0425] Clp-Hyp-Gly-Lys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:376);

[0426] Clp-Hyp-Gly-Clp-Lys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:377);

[0427] Clp-Hyp-Gly-Clp-Hyp-Gly-Lys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:378);

[0428] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Lys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:379);

[0429] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Lys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:380);

[0430] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Lys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:381);

[0431] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Lys-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:382);

[0432] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Lys-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:383);

[0433] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Lys-Hyp-Gly-Clp-Hyp-Gly (SEQ ID NO:384);

[0434] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Lys-Gly-Clp-Hyp-Gly (SEQ ID NO:385);

[0435] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Lys-Hyp-Gly (SEQ ID NO:386); and

[0436] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Lys-Gly (SEQ ID NO:387).

[0437] Another suitable CMP for use according to the invention is a CMP having or comprising the sequence Hyp-Flp-Gly-Hyp-Flp-Gly-Hyp-Flp-Gly-Hyp-Flp-Gly-Hyp-Flp-Gly-Flp-Gly-Hyp-Flp-Gly (SEQ ID NO:388).

[0438] Further preferred CMPs for use according to the invention include those having the sequences Gly3-(Pro-Hyp-Gly)6 (SEQ ID NO:397), Gly3-(Pro-Flp-Gly)6 (SEQ ID NO:398), Gly3-(Pro-Hyp-Gly)7 (SEQ ID NO:399), Gly3-(Pro-Flp-Gly)7 (SEQ ID NO:400), Gly3-(Pro-Hyp-Gly)8 (SEQ ID NO:401), Gly3-(Pro-Flp-Gly)8 (SEQ ID NO:402), Gly3-(Pro-Hyp-Gly)9 (SEQ ID NO:403), Gly3-(Pro-Flp-Gly)9 (SEQ ID NO:404), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:405), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:406), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:407), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:408), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:409), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:500), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:501), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:502), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:503), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:504), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:505), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:506), (Pro-Hyp-Gly)6-Tyr (S ID NO:406), (Pro-Hyp-Gly)7-Tyr (SEQ ID NO:407), (Pro-Flp-Gly)7-Tyr (SEQ ID NO:408), (Pro-Hyp-Gly)8-Tyr (SEQ ID NO:409), (Pro-Flp-Gly)8-Tyr (SEQ ID NO:410), Cys-(Pro-Hyp-Gly)3(SEQ ID NO:411), Cys-(Pro-Flp-Gly)3(SEQ ID NO:412), Cys-(Pro-Hyp-Gly)5(SEQ ID NO:413), Cys-(Pro-Flp-Gly)5(SEQ ID NO:414), Cys-(Pro-Hyp-Gly)7(SEQ ID NO:415) and Cys-(Pro-Flp-Gly)7(SEQ ID No. 4,313,663, as well as other similar CMPs that may be suitable for use as agents for collagen remodeling in vitro and in vivo for use in therapeutic and / or diagnostic methods (see, e.g., U.S. Pat. Nos. 8,283,414 and 8,883,964, which are incorporated by reference in their entireties).

[0439] Preferred CMPs according to this aspect of the invention include CMPs having an amino acid sequence corresponding to SEQ ID NOs: 1-14, 66-94, 107-135, 136-140, 192-220, 233-261, 260-264, 280, 281, 293, 294, 306, 307, 318-346, 347, 348, 359-388, and 397-416. Particularly preferred are CMPs having an amino acid sequence corresponding to SEQ ID NOs: 1, 2, 4, 5, 6, 9, 10-27, 81-94, 122-135, 207-220, 248-261, 333-346, 374-388, and 397-416. Even more preferred are CMPs having amino acid sequences corresponding to SEQ ID NOs: 1, 2, 4, 5, 6, 9, 388 and 397-416 (in the case of CMPs that are not directly conjugated to one or more pharma- ceutically active ingredients or biologics or to one or more diagnostic labels or agents), and CMPs having amino acid sequences corresponding to SEQ ID NOs: 10-27, 81-94, 122-135, 207-220, 248-261, 333-346, 374-388 and 397-416 (in the case of CMPs that are directly conjugated to one or more pharma-ceutically active ingredients or biologics or to one or more diagnostic labels or agents). Of course, one of skill in the art will understand based on knowledge in the art and the teachings herein that the CMP may contain more than one cysteine, methionine and / or lysine residue, and that at least one additional cysteine, methionine and / or lysine residue, or any combination thereof, may be substituted for at least one proline residue, at least one hydroxyproline residue, at least one fluoroproline residue and / or at least one chloroproline residue in any of the above CMP sequences that contain at least one proline residue, at least one hydroxyproline residue, at least one fluoroproline residue and / or at least one chloroproline residue. One of skill in the art will also understand based on the teachings herein and information readily available in the art that other combinations of amino acid substitutions are possible and are within the scope of the invention.

[0440] The CMPs described herein are suitable for a variety of purposes. For example, as described in more detail elsewhere herein, the CMPs may be used for a variety of therapeutic or prophylactic applications by being applied or introduced directly into the body of a human or veterinary subject, particularly at the site of collagen breakdown or potential collagen breakdown, where the CMPs described herein go directly to the collagen breakdown site, pair with the broken collagen chains, stabilize the collagen structure against further breakdown, and in some cases, modify the native collagen triple helix at the collagen breakdown site. Such applications are useful for promoting the repair and strengthening of broken collagen at the site of injury or potential injury or breakdown, for example, in wounds, diseases, structural abnormalities or disorders (e.g., scars, wrinkle formation, etc.) affecting skin, tendons, ligaments, cartilage, bone, and other collagen-containing structures and organs. The CMPs described herein are also useful for providing biocompatible coatings for certain medical devices to promote healing of injuries and disorders in areas of the body where the devices are used to treat or prevent diseases, disorders, and structural abnormalities or injuries in human and veterinary subjects, particularly where the diseases, disorders, and structural abnormalities or injuries involve the breakdown of collagen and / or collagen-containing structures. The CMPs described herein are also useful for providing unique delivery vehicles suitable for delivering a variety of therapeutic compounds, compositions, and medicaments to the site of disease, disorders, and structural abnormalities or injuries in human and veterinary subjects, particularly for use in treating, preventing, or ameliorating diseases, disorders, pathologies, and structural abnormalities or injuries where collagen breakdown causes, is associated with, or is co-localized at the site of the disease, disorder, and structural abnormality or injury. In further embodiments, the CMPs described herein are useful for providing diagnostic agents suitable for diagnosing or detecting diseases, disorders, structural abnormalities, or injuries in human and veterinary subjects.In certain aspects of interest, the CMP may be co-formulated with or directly or indirectly conjugated to one or more suitable diagnostic compounds, agents, labels, and the like (see, e.g., U.S. Pat. Nos. 8,283,414 and 8,883,964, the disclosures of which are incorporated herein by reference in their entireties.) Other suitable uses for the CMPs described herein and employed in certain aspects of the invention will be readily apparent to those of skill in the art based on the disclosures herein and information readily available in the art.

[0441] In certain embodiments, the CMPs described herein are suitable for formation into films, wafers, membranes, or gels that include one or more of the CMPs in a form suitable for introduction or implantation into a human or animal for therapeutic, prophylactic, or diagnostic applications, such as those described herein and those familiar to those of skill in the art. For example, films, wafers, membranes, spheres, nanoparticles, or gels can be formed from solutions of one or more of the CMPs described herein using methods such as those described in U.S. Patent Nos. 6,197,934, 6,448,378, and 9,289,396, the disclosures of which are all incorporated herein by reference in their entireties. Alternatively, films, wafers, membranes, spheres, nanoparticles or gels can be prepared using a variety of materials including atelocollagen (see U.S. Pat. Nos. 6,197,934, 6,448,378 and 9,289,396), copolymers of poly(lactic acid) and poly(glycolic acid) (PLGA) (see Bala, I., et al., Crit. Rev. Ther. Drug Carrier Syst. 21(5):387-422 (2004)), and other materials known to those skilled in the art (see, e.g., Kumar, V., et al., eds., "Polymer Gels: Perspectives and Applications", ISBN 978-981-10-6079-3, Singapore: Springer Science+Business Media, Inc., 2007). (2018)) and one or more of the CMPs can be suitably incorporated into the film, wafer, membrane, sphere, nanoparticle, gel, etc., during its formation by including the CMP in a solution at a concentration of about 1%-99%, about 2%-95%, about 3%-90%, about 4%-90%, about 5%-90%, about 10%-90%, about 15%-90%, about 20%-90%, about 25%-90%, about 25%-85%, about 25%-75%, about 25%-50%, and about 35%-50%, etc. Other suitable amounts or concentrations of the CMPs described herein that can be suitably included in a solution during the formation of the film, wafer, membrane, sphere, nanoparticle, gel, etc. will be readily apparent to one of ordinary skill in the art from the teachings of the present specification and information readily available in the art.In certain such embodiments, one or more therapeutic compounds as described herein and / or one or more CMP-TC conjugates as described herein may be suitably incorporated into a solution from which a film, wafer, membrane, sphere, nanoparticle, gel, etc. is formed. Alternatively, in a related aspect, once one or more films, wafers, membranes, spheres, nanoparticles, gels, etc. have been formed as described above, they may be treated or coated with one or more CMPs and / or CMP-TC conjugates as described herein prior to use in a therapeutic, prophylactic or diagnostic method, such as a method as described herein, by immersing the film, wafer, membrane, sphere, nanoparticle, gel, etc. in a solution, particularly a buffered aqueous solution, containing a suitable amount or concentration (e.g., an amount or concentration as described herein) of one or more CMPs or CMP-TC conjugates as described herein and then drying the film, wafer, membrane, etc.

[0442] Linkage / Conjugation to CMP

[0443] In certain embodiments of the invention, the CMPs described herein are suitably linked or conjugated to one or more therapeutic or diagnostic compounds to produce a CMP conjugate compound. In such embodiments of the invention, the CMP-therapeutic or CMP-diagnostic compound conjugate compounds can then be introduced into the body of a human or veterinary subject in a method for treating and / or preventing and / or diagnosing particular diseases, disorders and structural abnormalities in a human or veterinary subject suffering from said diseases, disorders and structural abnormalities. Thus, in certain embodiments, the invention also provides the use of the CMPs described herein linked or conjugated to one or more therapeutic compounds to produce a conjugated CMP, compositions comprising such conjugated CMPs (which may optionally include one or more additional therapeutic or medicamentously active ingredients), methods of producing the conjugates, and methods of using the conjugates and compositions in the treatment, prevention and diagnosis of various diseases, disorders and conditions in human and veterinary subjects.

[0444] A conjugate of a CMP and at least one therapeutic compound according to this aspect of the invention (sometimes referred to herein as a "CMP-TC conjugate") comprises at least one CMP as described herein linked to at least one therapeutic compound to form a CMP-TC conjugate. CMPs suitable for use in this aspect of the invention include any of the CMPs described herein, including CMPs having an amino acid sequence corresponding to any one of SEQ ID NOs:1-387, particularly CMPs having an amino acid sequence corresponding to any one of SEQ ID NOs:1-14, 66-94, 107-135, 136-140, 192-220, 233-261, 260-264, 280, 281, 293, 294, 306, 307, 318-346, 347, 348, 359-388 and 397-416, particularly CMPs having an amino acid sequence corresponding to SEQ ID NOs:10-27, 81-94, 122-135, 207-220, 248-261, 333-346, 374-388 and 397-416. Other suitable CMP sequences will be readily apparent to those of skill in the art based on the teachings contained herein. For example, CMPs in which at least one, and optionally more than one, cysteine, methionine or lysine residue is replaced with at least one, and optionally more than one, proline, hydroxyproline, fluoroproline or chloroproline residue of SEQ ID NOs:1-9 are particularly suitable for use in producing the CMP-TC conjugates provided by and used in the present invention. Examples of such suitable CMPs include CMPs having amino acid sequences corresponding to SEQ ID NOs: 10-27, 81-94, 122-135, 207-220, 248-261, 333-346, 374-388 and 397-416.

[0445] The CMP and CMP-TC described herein and provided and used in the present invention are familiar to those skilled in the art based on the teachings of the present specification and information readily available in the art. For example, CMP can be synthesized using standard protein / peptide synthesis techniques, such as those described in U.S. Patent Nos. 5,973,112, 7,122,521 and 7,858,741, and U.S. Patent Publication No. 2007 / 0275897A1, the disclosures of which are all incorporated herein by reference in their entirety. Synthesis of CMP can also be achieved by purchasing custom-synthesized CMPs commercially produced, for example, by Bachem (Torrance, CA, USA) and RS Synthesis (Louisville, KY, USA). In other embodiments, synthesis of CMP can be achieved using genetic engineering and recombinant expression of CMP from prokaryotic or eukaryotic expression systems (see, for example, Buechter, DD, et al., J. Biol. Chem. 278(1):645-650 (2003)).

[0446] In synthesizing the peptides described herein, in certain embodiments, it is preferred to use specific stereochemical configurations for amino acid substitutions, particularly when hydroxyproline, fluoroproline, or chloroproline are used.

[0447] (1) When hydroxyproline replaces proline at the Xaa position in the Xaa-Yaa-Gly trimer described above, in certain embodiments, the hydroxyproline has a (2R,4S) stereochemistry, or a cis or trans, preferably a cis, stereochemistry.

[0448] (2) When hydroxyproline replaces proline at the Yaa position in the Xaa-Yaa-Gly trimer described above, in certain embodiments, the hydroxyproline has a (2R,4S) stereochemical configuration, or a cis or trans, preferably a cis, stereochemical configuration.

[0449] (3) When fluoroproline replaces proline at the Yaa position in the Xaa-Yaa-Gly trimer described above, in certain embodiments, the hydroxyproline has a (2R,4S) stereochemistry, or a cis or trans, preferably cis, stereochemistry.

[0450] (4) When chloroproline replaces proline at the Yaa position in the Xaa-Yaa-Gly trimer described above, in certain embodiments, hydroxyproline has a (2R,4S) stereochemistry, or a cis or trans, preferably cis, stereochemistry.

[0451] Other suitable stereochemical configurations can be empirically identified without reliance on undue experimentation and will be readily appreciated by those of skill in the art. As noted above, certain CMPs provided by and used in the present invention may contain one or more substitutions, such as, for example, replacing one or more cysteine ​​and / or one or more methionine residues with one or more prolines in a given CMP multimer. Such substitutions are suitably achieved by adding those residues to the growing CMP peptide chain during the synthesis process using standard peptide synthesis methods, such as those described elsewhere herein and known in the art.

[0452] Once produced, the CMP is suitable for use in producing a CMP-TC of the invention, i.e., a therapeutic or diagnostic composition of the invention, by linking one or more therapeutic compounds to the CMP. In a particular embodiment, (a) a collagen pseudopeptide having an amino acid sequence corresponding to any one of SEQ ID NOs: 1-387, particularly a CMP having an amino acid sequence corresponding to any one of SEQ ID NOs: 1-14, 66-94, 107-135, 136-140, 192-220, 233-261, 260-264, 280, 281, 293, 294, 306, 307, 318-346, 347, 348, 359-388, and 397-416 ... The CMP-TCs of the invention can be made by a method that includes providing a CMP having NOs: 10-27, 81-94, 122-135, 207-220, 248-261, 333-346, 374-388, and 397-416, (b) providing at least one therapeutic or diagnostic compound suitable for conjugation to the CMP, and (c) linking the therapeutic or diagnostic compound, directly or indirectly, to the CMP. In certain cases, particularly when the therapeutic compound is a small peptide biocompound, the therapeutic compound can be directly linked to the CMP via a peptide bond, for example, by simply extending the synthesis of the peptide beyond the carboxy terminus of the CMP and linking the amino terminal amino acid of the therapeutic compound to the carboxy terminal amino acid of the CMP via a peptide bond. One example of such a CMP-TC is a peptide conjugate in which the wound healing peptide known as substance P is linked to a CMP having the amino acid sequence Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:389) as described herein.

[0453] Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:390);

[0454] Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Hyp-Pro-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:391);

[0455] Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:392);

[0456] Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Flp-Hyp-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:393);

[0457] Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Clp-Hyp-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:394);

[0458] Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Pro-Flp-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (SEQ ID NO:395);

[0459] Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Pro-Clp-Gly-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met(SEQ ID NO:396)。

[0460] In other methods of the invention, one or more therapeutic or diagnostic compounds are suitably conjugated or linked to the CMP via a covalent bond other than a peptide bond (see, e.g., U.S. Patent Nos. 3,283,414 and 3,883,964, which are incorporated herein by reference in their entirety). For example, a therapeutic compound can be directly linked to a cysteine ​​or methionine residue of a CMP as described herein by covalently binding a hydroxyl or amino group at an amino acid residue (e.g., a lysine residue) of the therapeutic or diagnostic compound (if it is a biomolecule) to a sulfhydryl group at the cysteine ​​or methionine residue of the CMP. Alternatively, if the CMP does not contain a cysteine ​​or methionine residue, one or more therapeutic or diagnostic compounds can be linked or conjugated to the CMP by reaction of a hydroxyl or amino group of the CMP with a sulfhydryl group at an amino acid residue (e.g., at a cysteine ​​or methionine residue) of the therapeutic or diagnostic compound (if it is a biomolecule). In yet another alternative conjugation method, a therapeutic compound can be directly linked to a lysine residue of a CMP as described herein by covalently linking the therapeutic compound to an amino group on the lysine, for example, using NHS ester conjugation (see, e.g., Mattson, G., et al., Molec. Biol. Rep. 17:167-183 (1993); Grabarek, Z. and Gergely, J., Anal. Biochem. 185:131-135 (1990); Staros, JV et al., Anal. Biochem. 156:220-2 (1986); Timkovich, R., Anal. Biochem. 79:135-43 (1977)). Such direct covalent linkage or conjugation of a CMP to a therapeutic / diagnostic compound can be accomplished using standard reaction techniques well known to those skilled in the art of organic chemistry.

[0461] In other embodiments, particularly those in which the therapeutic or diagnostic compound is not a biologic (and therefore does not have a peptide structure or amino acid residues with groups suitable for linking to a cysteine, methionine, lysine or other residue of the CMP), such as a small molecule organic or inorganic therapeutic or diagnostic compound, at least one therapeutic or diagnostic compound is indirectly linked to the collagen pseudo-peptide through the use of a linking means. In such embodiments, the linking means has two linkable ends, one linking to an amino acid residue of the CMP, preferably a sulfhydryl group on a cysteine ​​or methionine residue or an amino group on a lysine residue, and the other linking to a hydroxyl or amino group of the therapeutic or diagnostic compound. For example, in certain such embodiments, the linking means comprises at least one polymer chain having a first end and a second end, the first end of the polymer chain being attached to a sulfhydryl group on a cysteine ​​or methionine residue or an amino group on a lysine residue of the collagen pseudo-peptide, and the opposite or second end of the polymer chain being attached to an amino or hydroxyl group of the therapeutic compound. In embodiments where the therapeutic or diagnostic compound is a biologic that is not suitable for direct linkage by peptide synthesis as described elsewhere herein, the second end of the linking means can be linked to an amino group on an amino acid residue, such as a lysine residue, of the biotherapeutic or diagnostic compound. Suitable such linking means are well known to those of skill in the art. For example, one linking means suitable for use according to this aspect of the invention comprises a moiety that is a polymer chain that includes a sulfhydryl linking group, such as maleimide, at one end (particularly the CMP linking end) and an amino linking group, such as N-hydroxysuccinimide, at the other end (particularly the therapeutic or diagnostic compound linking end). In certain such embodiments, the polymer chain is a linear polyethylene glycol chain that includes at least 4 ethylene glycol monomers, for example 4 to 50 ethylene glycol monomers, 10 to 40 ethylene glycol monomers, 15 to 30 ethylene glycol monomers, 15 to 25 ethylene glycol monomers, 20 to 25 ethylene glycol monomers, particularly 4, 6, 8, 12, 20, 22, 23, 24 or 25 ethylene glycol monomers.Suitable linking means for linking one or more therapeutic or diagnostic compounds to the CMP by the methods described herein are commercially available, for example from Thermo Fisher Scientific (Waltham, Massachusetts) (e.g., SM(PEG)6, SM(PEG)8, SM(PEG)12 and SM(PEG)24). The length of the polymer chain can be adjusted to modulate the bioavailability and persistence of the therapeutic or diagnostic compound in vivo. The use of longer polymer chains, for example, polymers containing 24 ethylene glycol monomers, increases the bioavailability of the compound when the CMP-TC is introduced into the body of a human or veterinary subject, while the use of shorter polymer chains, for example, polymers containing 6 ethylene glycol monomers, decreases the bioavailability of the therapeutic or diagnostic compound and increases persistence (in other words, delays or sustains release). Other conjugates using linear or star-shaped PEG moieties that can be suitably made using the CMPs of the invention and used in the therapeutic and diagnostic methods of the invention are disclosed in U.S. Pat. Nos. 8,283,414 and 8,883,964, which are incorporated herein by reference in their entireties. Thus, according to certain aspects of the present invention, at least one therapeutic compound contains at least one reactive hydroxyl group that can be crosslinked to the collagen pseudopeptide using a polymer linker.

[0462] According to the present invention, other indirect linking methods of conjugating one or more therapeutic or diagnostic compounds into or onto the CMP are also suitable for use. For example, at least one therapeutic or diagnostic compound can be included in at least one nanoparticle that is linked to the collagen pseudopeptide via a linking means, such as those described herein. Alternatively, the collagen pseudopeptide can suitably include at least one biotin moiety, and the therapeutic molecule can suitably include at least one avidin or streptavidin moiety, with the collagen pseudopeptide being linked to the therapeutic or diagnostic compound by the biotin moiety of the collagen pseudopeptide binding to the avidin or streptavidin moiety of the therapeutic or diagnostic compound. Of course, alternative methods are also suitable for use, where the collagen pseudopeptide can suitably include at least one avidin or streptavidin moiety, and the therapeutic or diagnostic compound can suitably include at least one biotin moiety, with the collagen pseudopeptide being linked to the therapeutic compound by the biotin moiety of the collagen pseudopeptide binding to the avidin or streptavidin moiety of the collagen pseudopeptide.

[0463] Thus, according to certain embodiments of the invention, a therapeutic or diagnostic compound may be suitably linked directly to a CMP as described herein. In other embodiments of the invention, one or more therapeutic or diagnostic compounds may be linked indirectly to a CMP as described herein, for example, by the use of a spacer, linker, or bridging moiety. It should be understood that whether one or more therapeutic compounds are linked directly or indirectly to a CMP, the linkage produces a conjugate of the CMP and one or more therapeutic compounds, which may be defined herein as a CMP-TC conjugate.

[0464] Suitable therapeutic or diagnostic compounds for linking or conjugating to a CMP to produce a CMP-TC of the invention include any compound that has been shown to have specific therapeutic or preventative properties for one or more of a disease, disorder, physical condition or symptom when introduced into a human or veterinary subject suffering from or susceptible to the disease, disorder, physical condition or symptom. Any therapeutic or diagnostic compound can be used in the conjugates, compositions and methods of the invention, provided that the therapeutic or diagnostic compound can be conjugated or linked to at least one CMP in accordance with the teachings herein. Suitable such therapeutic compounds may be biologic or non-biological (e.g., so-called "small molecule") therapeutic compounds. Compounds suitable for use include steroidal anti-inflammatory drugs (e.g., prednisolone or a pharma- ceutically acceptable salt thereof, such as prednisolone acetate), non-steroidal anti-inflammatory drugs (e.g., acetylsalicylic acid, acetaminophen, ibuprofen, naproxen, nepafenac, bromfenac, diclofenac, flurbiprofen, ketoprofen, ketorolac, and indene derivatives (see, e.g., U.S. Pat. No. 7,601,874, which is incorporated herein by reference in its entirety, for other indene derivatives suitable for use as active pharmaceutical ingredients, such as indomethacin and sulindac (Clinoril), and pharma-ceutical acceptable salts, esters, and derivatives thereof), local anesthetics (e.g., tetracaine, lidocaine, oxybufinamide, benzodiazepine, benzocaine, benzoyl peroxidase, benzodiazepine, benzoyl peroxidase ... procaine and proparacaine), vitamins or vitamin derivatives or vitamin precursors (e.g., retinol, tretinoin, retinal, carotenes and other retinoids and retinoid derivatives or precursors, folate, α-tocopherol, calciferol, phylloquinone, menadione and other vitamin K forms, precursors or derivatives, and ascorbate, etc.), therapeutic enzymes or therapeutic fragments thereof (e.g., collagenases and serine proteases, or therapeutically active fragments thereof), antibiotics (e.g., aminoglycoside antibiotics (e.g., gentamicin, tobramycin, paromomycin, kanamycin, neomycin, and amikacin, and pharma- ceutical acceptable salts or esters thereof, e.g., tobramycin sulfate),Fluoroquinolone antibiotics (e.g., moxifloxacin, gatifloxacin, levofloxacin, gemifloxacin, ciprofloxacin, norfloxacin, and ofloxacin, as well as pharma- ceutically acceptable salts, esters, or derivatives thereof, such as moxifloxacin hydrochloride, ciprofloxacin hydrochloride, and gatifloxacin hydrochloride), sulfonamide antibiotics (e.g., sulfacetamide, sulfadiazine, sulfadimidine, sulfafurazole (sulfisoxazole), sulfisomidine (sulfadoxine), sulfadoxine, sulfadox ... phamethoxazole, sulfamoxole, sulfanitran, sulfadimethoxine, sulfamethoxypyridazine, sulfamethoxydiazine, sulfamethopyrazine and terephytil, and pharma- ceutical acceptable salts, esters or derivatives thereof), β-lactam antibiotics (e.g., penicillin or its derivatives (e.g., penicillin G, penicillin V, benzylpenicillin and phenoxymethylpenicillin), dicloxacillin, flucloxacillin, oxacillin, nafcillin, amoxicillin, ampicillin, ticarcillin, piperacillin, , ritipenem, carbapenems (e.g., ertapenem, doripenem, imipenem, and meropenem, and pharma- ceutically acceptable salts, esters, or derivatives thereof), cephapenems (e.g., cefazolin, cephalexin, cefadroxil, cephapirin, cefaclor, cefotetan, cephamycin (cefoxitin), cefprozil, cefuroxime axetil, ceftriaxone, ceftazidime, cefoperazone, cefdinir, cefcapene, cefdaloxime, ceftizoxime, cefmenoxime, ceftoxime, cefpiramide, cefpodoxime, cefpiramide ... ceftibutene, cefditoren, cefepime, ceftaroline fosamil, ceftolozane, ceftobiprole, ceftiofur, cefquinome and cefovecin, and pharma- ceutically acceptable salts, esters or derivatives thereof), monobactams (e.g., aztreonam, or pharma-ceutically acceptable salts, esters or derivatives thereof) and β-lactamase inhibitors (e.g., sulbactam, tazobactam, clavulanic acid and avibactam, and pharma-ceutically acceptable salts, esters or derivatives thereof) or cyclic peptide antibiotics (e.g., cyclosporine),Therapeutic monoclonal antibodies or therapeutic fragments thereof (e.g., adalimumab, altumomab, atezolizumab, atolizumab, bevacizumab, canakinumab, catumaxomab, certolizumab, cetuximab, clivatuzumab, edrecolomab, efalizumab, fontolizumab, girentuximab, golimumab, infliximab, labetuzumab, MABp1 (Xilonix™), natalizumab, nimotuzumab, nivolumab, oregovomab, panitumumab, pembroliz ... tuzumab, pemtumomab, pertuzumab, ramucirumab, ranibizumab, rituximab, ruplizumab, tracatuzumab, tocilizumab, trastuzumab, ustekinumab, vedolizumab, visilizumab, votumbam, zalutumumab, and zanolimumab, as well as active fragments, combinations, or conjugates thereof), therapeutic fusion proteins (in certain embodiments, aflibercept (Regeneron), etanercept (Amgen), alefacept (Astellas), Pharma), abatacept (Bristol-Myers Squibb), rilonacept (regeneron), romiplostim (Amgen), and belatacept (Bristol-Myers Squibb), prostaglandin analogues (e.g., latanoprost, travoprost, tafluprost, unoprostone, netarsudil, tatanoprostene bunod, netarsudil, and bimatoprost, and pharma- ceutical acceptable salts, esters, and derivatives thereof), growth factors (e.g., EGF, PDGF, TGF-β, IGF-1, VEGF, FGF-β, and IGF-1), or therapeutic or growth-promoting (particularly skin growth-promoting) fragments thereof, neuropeptides (e.g., substance P (SEQ ID NO: 1) NO:389), α-adrenergic antagonists (e.g., brimonidine, clonidine and apraclonidine, and pharma- ceutical acceptable salts, esters or derivatives thereof), β-adrenergic antagonists (e.g., timolol, propranolol, atenolol, levobunolol, carteolol, betaxolol, and pharma- ceutical acceptable salts, esters and derivatives thereof, such as timolol maleate), cell surface receptor antagonists (e.g., lifitegrast or etanercept), carbonic anhydrase inhibitors (e.g., dorzolamide,These include, but are not limited to, brinzolamide, methazolamide and acetazolamide, as well as pharma- ceutical acceptable salts, esters and derivatives thereof, e.g., dorzolamide hydrochloride, as well as pharma-ceutical acceptable salts, esters and derivatives thereof. Concomitant administration of the CMPs described herein with certain therapeutic compounds of interest, either as CMP-TC conjugates or simply as one or more CMPs and one or more TCs applied in admixture or individually, can prevent, attenuate or reduce one or more adverse side effects of the therapeutic compounds. For example, it is known that therapeutic administration of certain fluoroquinolone antibiotics can damage collagen and collagen-containing structures (e.g., tendons) in human or veterinary subjects treated with the fluoroquinolone (see, e.g., "FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects," accessed November 6, 2017, at https: / / www.fda.gov / Drugs / DrugSafety / ucm511530.htm). Thus, when one or more of the CMPs described herein are administered simultaneously or co-administered with one or more fluoroquinolone antibiotics to a human or veterinary subject in need of fluoroquinolone treatment, the CMPs may penetrate and repair areas of damaged collagen in vivo, thereby allowing the patient to receive the therapeutic benefits of the fluoroquinolone while mitigating, ameliorating or avoiding collagen destruction caused by the treatment.

[0465] Other suitable therapeutic compounds for use in the CMP-TC compounds, compositions and conjugates of the invention include other non-biological small molecule therapeutic compounds, including, but not limited to, alkylating agents, antitumor antibiotics, antimetabolites, hormonal agents, plant alkaloids, angiogenesis inhibitors, GnRH agonists and tyrosine kinase inhibitors, etc. Examples of such non-biological small molecule therapeutic compounds suitable for use in accordance with the present invention include, but are not limited to, nitrosoureas, lenalidomide, imatinib, penatrexed, vortexomib, abiraterone acetate, everolimus, taxol, docetaxel, paclitaxel, carbazitaxel, mitoxantrone, carboplatin, cisplatin, gemcitabine, doxorubicin, casodex, flutamide, enzalutamide, abiraterone, sipuleucel-T and ketoconazole. Other suitable non-biological small molecule therapeutic compounds that may be advantageously used in the formation of the CMP-TC conjugates of the present invention, particularly in the manufacture of CMP-TC conjugates useful for treating certain cancers and preventing tumor metastasis, include lysyl oxidase (LOX), lysyl oxidase-like 1 (LOXL1) enzyme, and lysyl oxidase-like 2 (LOXL2) enzyme.Such inhibitors may find therapeutic application in treating and / or preventing certain cancers and metastasis of solid tumors (see, e.g., U.S. Pat. Nos. 5,201,456, 5,120,764, 5,252,608, 8,461,303, 8,658,167, 8,680,246, 9,176,139, 9,255,086, and 9,289,447, the disclosures of which are all incorporated by reference herein in their entireties; see also Erler, JT, et al., Nature 440:1222-1226 (2006); Erler, JT, et al., Cancer Cell 15(1):35-44 (2009); Bondareva, A., et al., PLoS ONE 4(5):e5620 (2009); Granchi, C., et al., ChemMedChem 4 (10:1590-1594 (2009); and Fang, M., et al., Tumor Biol. 35:2871-2882 (2014)). In a related aspect of the invention, CMP-TC conjugates comprising one or more inhibitors of LOX or LOX-like enzymes are suitably used to treat and / or prevent certain fibrotic diseases and disorders mediated by oxidoreductases such as LOX and LOX-like enzymes (e.g., LOXL1 and LOXL2) in human and veterinary subjects. Fibrotic diseases and disorders that are suitably treated and / or prevented by this aspect of the invention include, but are not limited to, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, surgical scarring, systemic sclerosis, scleroderma, keloid formation, proliferative vitreoretinopathy, and other fibrotic diseases and disorders well known to those skilled in the art.Particularly useful inhibitors of LOX and LOX-like proteins include β-aminopropionitrile and certain derivatives and prodrugs thereof (see, e.g., U.S. Pat. Nos. 5,201,456, 5,120,764, 5,252,608, 8,461,303, 8,680,246, 9,176,139 and 9,255,086, all of which are incorporated herein in their entireties), as well as antibodies (which may be polyclonal or, preferably, monoclonal) that bind to and inhibit the activity and function of LOX and LOX-like enzymes, and fragments or portions thereof (see, e.g., U.S. Pat. No. 8,461,303, the disclosure of which is incorporated herein in its entirety).

[0466] In further embodiments, compounds or compositions comprising one or more CMPs and one or more antigens can be made by mixing or co-formulation of one or more CMPs with one or more antigens (optionally with one or more pharma- ceutical suitable carriers or excipients), or within other compounds or compositions in which one or more antigens are directly or indirectly linked or conjugated to one or more CMPs. According to certain such aspects, the antigen may be an intact antigen, or an antigenic determinant or fragment thereof (e.g., a hapten), capable of eliciting an immune response in a human or veterinary subject when presented to the immune system of a human or veterinary subject in the appropriate physiological context, for example, in the form of administration of the compound, conjugate or composition in the form of a vaccine or immunizing agent to the human or veterinary subject. Compounds, conjugates and compositions useful in such embodiments can be made by co-formulation or direct or indirect conjugation according to the methods described elsewhere herein for co-formulation and conjugation of therapeutic compounds with CMPs. Antigens or portions thereof suitable for use in the subject compounds, conjugates and compositions, and therefore for the methods of their use, include any molecule or particle, or portion thereof, capable of eliciting an immune response in a human or veterinary subject, including, but not limited to, antigens (e.g., proteins, toxins, lipids and other antigenic moieties, molecules, or complexes) originating from or produced by bacteria (wherein the antigen may comprise the whole bacterium or a portion thereof, e.g., a cell wall or cell membrane component, a nuclear component, or a toxin produced by the bacterium), a virus (wherein the antigen may be the whole virus particle or a portion thereof, e.g., a capsule component (e.g., a protein or lipid or a portion thereof), a nuclear component, or an enzyme encoded by or part of the virus particle), a protozoan, a fungus, a plant (wherein the antigen or portion thereof may be an alloantigen or an autoantigen or a portion thereof), and the like. Examples of such antigens or portions thereof are well known to those of skill in the art.The compounds, compositions or conjugates are suitably used in methods for treating and / or preventing one or more disorders, diseases and conditions in human and veterinary subjects, for example by use of the compounds, compositions or conjugates in generating an immune response in a human or veterinary subject. In certain such methods, a disease or disorder in a human or veterinary subject is treated and / or prevented by administering one or more of the compounds, compositions or conjugates of this aspect of the invention to the human or veterinary subject, for example in the form of a vaccine or immunizing agent. The vaccine or immunizing agent is suitably formulated by methods well known in the art and administered in a form that generates an immune response against the antigen or a portion thereof by the human or veterinary subject, thereby treating and / or preventing a disease or disorder caused directly or indirectly by the antigen or a portion thereof. The vaccine or immunizing agent may be administered to a human or veterinary subject by any suitable route, such as orally, parenterally (including subcutaneously, intradermally, transdermally, intrathecally or intravenously), ocularly (e.g., in the form of drops, gels, wafers, or injections, as described elsewhere herein for administration of CMP-TC to the eye), intranasally, and other routes of administration well known to those skilled in the art. In such embodiments, the compounds, conjugates or compositions of the invention are suitably administered to a human or veterinary subject until an immune response sufficient to treat and / or prevent the targeted disease or disorder has been generated by the human or veterinary subject, and may be readministered as necessary to strengthen the immune response and / or sustain immunity to the target antigen or portion thereof.Diseases and disorders that are suitable to be treated by the methods of the invention include any disease or disorder involving or resulting from the activity of any foreign body acting on a cell, organ, organ system, body structure or body of human and veterinary subjects, including, but not limited to, infectious diseases, cancer, allergies and other immune hyperreactions (e.g., graft-versus-host or host-versus-graft disease), Stevens-Johnson syndrome, mucous membrane pemphigoid, toxic epidermal necrolysis, Behcet's disease uveitis, birdshot retinochoroidopathy, juvenile idiopathic arthritis (JIA) associated uveitis, multifocal choroiditis with panuveitis, necrotizing scleritis, serpiginous choroidopathy, sympathetic ophthalmia, Vogt-Koyanagi-Harada (VKH) disease, and non-infectious panuveitis.

[0467] Suitable diagnostic compounds that may be linked or conjugated to CMPs to produce the conjugates and compositions of the invention include fluorescent dyes (e.g., quantum dots, indocyanine green, fluorescein, rhodamine, merocyanine dyes, and near-infrared fluorescein dyes, etc.), particularly radioisotopes and each of the nuclides used in PET or SPECT. 11 C. 13 N, 15 O. 18 F, 66 Ga, 67 Ga, 68Ga, 60 Cu, 61 Cu, 62 Cu, 67 Cu, 64 Cu, 48 V, Tc-99m, 241 Am, 55 Co, 57 Co, 153 Gd, 111 In, 133 Ba, 82 Rb, 139 Ce, Te-123m, 137 Cs, 86 Y, 90 Y, 185 / 187 Re, 186 / 188 Re, 125The radioisotopes include, but are not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 112, 113, 114, 115, 116, 117, 120, 121, 122, 123, 124, 125, 126, 127, 130, 132, 133, 140, 142, 144, Methods for conjugating or linking diagnostic compounds to proteins such as CMPs are known in the art (see, e.g., U.S. Patent Publication No. 2012 / 0195828A1, the disclosure of which is incorporated herein in its entirety).

[0468] Use of CMP and CMP-TC conjugates

[0469] Thus, the invention provides methods of making compositions that are useful for treating, preventing, diagnosing or ameliorating a disease, disorder or medical condition in a human or veterinary subject. In yet another aspect, the invention provides methods of treating, preventing, diagnosing or ameliorating a disease, disorder or medical or physical condition in a human or veterinary subject using the compositions of the invention. Particularly preferred CMPs for use in this aspect of the invention include (Pro-Pro-Gly)7 (SEQ ID NO:1), (Flp-Pro-Gly)7 (SEQ ID NO:4), (Pro-Flp-Gly)7 (SEQ ID NO:5), (Flp-Hyp-Gly)7 (SEQ ID NO:6), (Clp-Hyp-Gly)7 (SEQ ID NO:9), (Hyp-Flp-Gly)7 (SEQ ID NO:388), Gly3-(Pro-Hyp-Gly)6 (SEQ ID NO:397), Gly3-(Pro-Flp-Gly)6 (SEQ ID NO:398), Gly3-(Pro-Hyp-Gly)7 (SEQ ID NO:399), Gly3-(Pro-Flp-Gly)7 (SEQ ID NO:400), Gly3-(Pro-Hyp-Gly)8 (SEQ ID NO:401), NO:401), Gly3-(Pro-Flp-Gly)8(SEQ ID NO:402), Gly3-(Pro-Hyp-Gly)9(SEQ ID NO:403), Gly3-(Pro-Flp-Gly)9(SEQ ID NO:404), (Pro-Hyp-Gly)6-Tyr (SEQ ID NO:405), (Pro-Flp-Gly)6-Tyr (SEQ ID NO:406), (Pro-Hyp-Gly)7-Tyr (SEQ ID NO:407), (Pro-Flp-Gly)7-Tyr (SEQ ID NO:408), (Pro-Hyp-Gly)8-Tyr (SEQ ID NO:409), (Pro-Flp-Gly)8-Tyr (SEQ ID NO:410), Cys-(Pro-Hyp-Gly)3(SEQ ID NO:411), Cys-(Pro-Flp-Gly)3(SEQ ID NO:412), Cys-(Pro-Hyp-Gly)5(SEQ ID NO:413),CMPs having the amino acid sequence of Cys-(Pro-Flp-Gly)5 (SEQ ID NO:414), Cys-(Pro-Hyp-Gly)7 (SEQ ID NO:415), or Cys-(Pro-Flp-Gly)7 (SEQ ID NO:416), as well as CMPs comprising, consisting essentially of, or consisting of one or more cysteine, methionine, or lysine residues, such as derivatives thereof, including those described elsewhere herein.

[0470] The CMP and CMP-TC conjugates of the invention, including solutions, gels, films, wafers, membranes, spheres, nanoparticles and suspensions comprising, consisting essentially of, or consisting of the CMP and / or CMP-TC conjugates of the invention, are suitably used or included in medicaments, or compositions for use as medicaments, for treating, preventing or ameliorating various diseases or disorders in human or veterinary subjects in need of such treatment or prevention. Other compositions provided by this aspect of the invention provide for the use of a CMP conjugated to one or more diagnostic compounds or molecules, such as one or more labeled probes, which are subsequently used as diagnostic agents, particularly in various in vivo or in situ tests and assays, to diagnose a disease, disorder or physical condition in a human or veterinary subject. The pharmaceutical or diagnostic compositions may contain, in addition to the CMP, CMP-TC conjugate, or CMP conjugated to one or more diagnostic compounds or molecules, one or more additional therapeutic compounds or pharma- ceutical active ingredients, including those described herein and known in the art (e.g., one or more antibiotics, one or more growth factors, autologous plasma rich in growth factors (PRGF), one or more cytokines, one or more antibody fragments thereof, one or more non-biological small molecule therapeutic compounds, and pharma- ceutical active salts, esters, and derivatives thereof, etc.). The compositions of the invention may additionally or alternatively contain one or more pharma- ceutical acceptable carriers or excipients. Pharmaceutically acceptable carriers or excipients suitable for use in the compositions and methods of the invention include, for example, one or more solvents (which may include water, organic solvents, or inorganic solvents), one or more buffers, one or more polymers, one or more salts, one or more sugars, one or more sugar alcohols, one or more disintegrants, one or more aerosolizing agents or carriers, and one or more drying agents, etc. Other pharma- ceutical acceptable carriers or excipients suitable for use in the compositions of the invention will be familiar to those of skill in the art.

[0471] Without wishing to be bound by theory, it is believed that the CMPs provided by the present invention and used in the methods of the present invention are particularly useful for repairing damaged collagen resulting from or associated with a variety of diseases, disorders, structural abnormalities, physical conditions and pathologies in human and veterinary subjects. For example, when collagen is structurally damaged, it fragments and breaks down into many smaller pieces that remain in the extracellular environment or enter the blood or lymphatic circulation. The fragments are ultimately phagocytosed or bound by scavenger cells or bind to cell surface receptors on somatic cells in the human or veterinary subject (which may include, for example, integrins, discoidin domain receptors, glycoprotein VI and leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1)). The receptors control cellular functions such as proliferation, differentiation, morphogenesis, tissue repair, adhesion, migration, homeostasis, immune function and wound healing, and are often disrupted or their functions or signaling systems are up- or down-regulated by the binding of the free collagen fragments. According to this theory, when CMP encounters damaged collagen or fragments thereof, it dynamically pairs or binds to the disrupted collagen triple helices and structurally repairs them, resulting in the restoration of cellular receptors to their proper levels of function and signaling activity, etc. Thus, the overall result of application of CMP to a human or veterinary subject having a disease, disorder, structural abnormality or injury involving or resulting from damaged collagen, in certain physiological circumstances, is an acceleration of the wound healing process, including rapid epithelial, endothelial or neuronal cell proliferation on the collagen matrix being repaired, resulting in the restoration of normal or near-normal structure and function of said cells, and the tissues, organs and organ systems containing said cells.

[0472] Diseases, disorders, physical conditions and medical conditions that are suitably treated, prevented, ameliorated or diagnosed using the compositions and methods of the present invention include, but are not limited to, ophthalmic diseases or disorders, skin diseases or disorders, cancer, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases or disorders, cardiovascular diseases or disorders, bone diseases or disorders, rheumatic diseases or disorders, and neurological or nervous system diseases or disorders.

[0473] Ocular diseases or disorders that may be treated, prevented, ameliorated, or diagnosed using the compositions and methods of the present invention include, but are not limited to, glaucoma, cataracts, vitreous adhesions or floaters, macular degeneration, dry eye syndrome (also known as dry eye disease), keratitis, non-infectious corneal ulcer, non-infectious corneal melt, infectious corneal ulcer, infectious corneal melt, conjunctivitis, Stevens-Johnson syndrome, scleritis, episcleritis, iritis, uveitis, vitritis, Behcet's disease uveitis, birdshot retinochoroidopathy, juvenile onset Acute or chronic corneal pain, including, but not limited to, idiopathic arthritis (JIA)-associated uveitis, multifocal choroiditis with panuveitis, necrotizing scleritis, serpiginous choroidopathy, sympathetic ophthalmia, Vogt-Koyanagi-Harada (VKH) disease, non-infectious panuveitis, ectasia, keratoconus, corneal lacerations, corneal erosions, corneal abrasions, periocular pain, extraocular pain, and post-herpetic neuralgia (particularly corneal pain resulting from corneal nerve injury or damage or denervation, e.g., Rosenthal, 2015;78(3):513-525; Belmonte, C., et al., Curr. Ophthalmol Rep. 2015;3(2):111-121), and anterior segment diseases and disorders including, but not limited to, ocular post-operative symptoms resulting from ocular surgery. Such post-operative eye conditions resulting from ocular surgery may be, for example, conditions occurring after cataract or glaucoma surgery that result in or lead to a post-operative eye condition that requires, inter alia, medication.Other ocular diseases or disorders that may be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include macular degeneration (wet, dry and age-related), retinitis pigmentosa, retinal tears or detachments, retinopathies (e.g., diabetic retinopathy), arterial or venous occlusions (e.g., BRAO (branch retinal artery occlusion), CRAO (central retinal artery occlusion), BRVO (branch retinal vein occlusion), CRVO (central retinal vein occlusion)), and optic neuritis (including, for example, AION (anterior ischemic optic neuropathy) and traumatic optic neuropathy), optic nerve atrophy (e.g., glaucomatous optic atrophy), cranial nerve 3 palsy, cranial nerve 4 palsy, cranial nerve 5 palsy. and other retina and posterior segment related disorders and diseases including, but not limited to, one or more neurological disorders affecting the eye or periocular area, including periocular and extraocular diseases, disorders or conditions such as cranial nerve palsies including, but not limited to, cerebral nerve palsies including, but not limited to, cerebral nerve palsies (e.g., trigeminal neuralgia and postherpetic herpetic neuralgia), cranial nerve 6 palsy and cranial nerve 7 palsy (e.g., Bell's palsy), and other retina and posterior segment related disorders and diseases including, but not limited to, posterior ocular diseases and disorders, particularly diseases and disorders affecting the retina, and other retina and posterior segment related disorders and diseases affecting the retinal epithelium, particularly the retinal pigment epithelium, retinal blood vessels and / or retinal nerves, cranial nerves or optic nerves.

[0474] According to this aspect of the invention, a method of treating or preventing an ocular disease, disorder or wound in a human or veterinary subject suffering from or susceptible to an ocular disease, disorder or wound comprises administering to the eye of the human or veterinary subject a composition as described herein, in particular a CMP or a CMP-TC conjugate and / or a composition comprising said conjugate. Without wishing to be bound by theory, the inventors speculate that in the field of ocular diseases or disorders, sufficient disruption of type I collagen occurs such that the CMP specifically targets the site of the ocular disease or disorder and, by inserting into the collagen structure, directly modifies the functional collagen matrix or, if the CMP is conjugated to a therapeutic compound, delivers the therapeutic compound to the site where it should act to treat, prevent or ameliorate the ocular disease or disorder. In certain such anterior segment diseases or disorders, such as acute or chronic corneal pain (including but not limited to periocular pain, extraocular pain and post-herpetic neuralgia), the denervated cornea has poor healing capabilities, so local therapies that can affect nerve regeneration are welcome therapies in this field. Because both acute and chronic pain are mediated by damaged corneal nerves (see, e.g., Rosenthal, P. and Borsook, D., Br J Ophthalmol. 2016;100(1):128-134; Theophanous, C., et al., Optom. Vis. Sci. 2015;92(9):e233-240; Belmonte, C., et al., Ocul. Surf. 2004;2(4):248-253; Belmonte, C., et al., Exp. Eye Res. 2004;78(3):513-525; Belmonte, C., et al., Curr. Ophthalmol Rep. 2015;3(2):111-121), therapeutic agents that may be beneficial to nerve health would be of clinical value to these patients. Based on the findings described herein (see Example 4 below) regarding the behavior of dorsal root ganglion cells when exposed to a CMP of the invention (SEQ ID NO:1) after the collagen support layer has been damaged, one would expect all cranial nerves to behave in a similar manner.Thus, the corneal nerve, a branch of the trigeminal nerve, is treated with one or more of the CMP or CMP-TC conjugates described herein, which are administered locally to the cornea. Repair and regeneration of the nerve subsequently results in corneal recovery and relief of pain, leading to amelioration of acute or chronic corneal pain.

[0475] The conjugate or composition is suitably applied to the eye in a dosage sufficient to treat or prevent an ocular disease, disorder or injury, and the ocular condition in said human or veterinary subject is then monitored over time for improvement of the disease or physical condition. Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml. In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25ng / ml to about 500ng / ml, for example, about 25ng / ml, about 30ng / ml, about 35ng / ml, about 40ng / ml, about 45ng / ml, about 50ng / ml, about 75ng / ml, about 100ng / ml, about 125ng / ml, about 150ng / ml, about 175ng / ml, about 200ng / ml, about 225ng / ml, about 250ng / ml, about 300ng / ml, about 350ng / ml, about 400ng / ml, about 450ng / ml or about 500ng / ml. In certain such embodiments, a concentration of about 25ng / ml to 250ng / ml is used. Further concentrations and amounts of the conjugates or compositions of the invention suitable for use in the methods can be readily determined by one of ordinary skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugates or compositions of the invention are subsequently periodically re-administered to the eye according to the administration and treatment schedules and protocols described herein, as well as other administration and treatment schedules and protocols familiar to those of ordinary skill in the art, until the ocular disease, disorder or wound is healed, prevented or ameliorated.In such embodiments, the conjugates or compositions of the invention for the treatment of anterior ocular diseases and disorders may be conveniently administered to the conjunctiva or subconjunctival of the eye or ocular surface, particularly by administering the conjugate or composition onto the ocular surface or into the subconjunctival fornix. In other embodiments involving the treatment, prevention, cure or diagnosis of posterior ocular diseases and disorders, the conjugates and compositions of the invention may be administered to the posterior ocular segment, e.g., at or near the retina, by mechanical introduction, such as by injection using a needle or other suitable device, or by administration of the conjugate or composition to the ocular surface in the form of droplets that transport or move the conjugate or composition (or a component thereof, e.g., a CMP or CMP-TC conjugate) to the posterior ocular segment (e.g., at or near the retina) (see, e.g., Example 5 below). Administration of the conjugate or composition can be achieved by any known means, including by applying the conjugate or composition to the eye in the form of one or more drops or aliquots of a solution, gel, or suspension containing the composition or conjugate, or by injection, or in the form of a solid material such as a wafer or film (e.g., as described herein) that is implanted into the ocular structure, or in the form of a mesh or patch, or by adhering to or encapsulating in one or more gels, spheres, or nanoparticles that are then delivered into the ocular structure. Other suitable methods of applying the conjugate or composition to the eye to achieve the therapeutic and diagnostic methods of the invention will be readily apparent to those of skill in the art.

[0476] Skin diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include, but are not limited to, skin wounds, scars, wrinkles, "skin shrinkage", skin cancer (e.g., melanoma, skin carcinoma, dermal sarcoma, histiocytoma), and skin burns, including sunburn. Other skin diseases or disorders that are suitably treated, prevented, ameliorated or diagnosed by the invention include psoriasis and eczema, shingles, irritant contact dermatitis and allergic contact dermatitis (e.g., poison ivy, poison oak or poison sumac).

[0477] According to this aspect of the invention, a method of treating or preventing a skin disease, disorder or wound in a human or veterinary subject suffering from or susceptible to a skin disease, disorder or wound comprises administering the compositions described herein, particularly CMP and CMP-TC conjugates, and compositions comprising said CMP and CMP-TC conjugates, to a site in the skin of the human or veterinary subject proximate to the location of a lesion that accompanies or causes the skin disease, wound or disorder. Without wishing to be bound by theory, the inventors speculate that in the area of ​​the skin disease or disorder, sufficient disruption of type I collagen has occurred such that the CMP specifically targets the site of the skin disease or disorder and inserts into the collagen structure, thereby directly modifying a functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, delivering the CMP and / or therapeutic compound to the site where they should act to treat, prevent or ameliorate the skin disease or disorder. Alternatively, a disease or disorder affecting the skin can be excised or removed from the skin (e.g., a skin cancer by surgical excision), and the skin wound resulting from said excision or removal can be treated with one or more compositions of the invention according to the methods described herein. In certain embodiments, one or more of the CMPs themselves, or one or more CMP-TC conjugates, or any combination thereof, can be introduced into the skin, particularly intraepidermally, intradermally, or subcutaneously, in the form of a so-called "cosmeceutical" (see, for example, Epstein, H., Clin. Dermatol. 27(5):453-460 (2009)). Particularly preferred CMP-TC conjugates or compositions for use in this aspect of the invention include those in which the therapeutic compound is substance P (SEQ ID NO;389), particularly those in which the CMP-TC conjugate has an amino acid sequence corresponding to any one of SEQ ID NOs: 390-396. Further particularly preferred CMP-TC conjugates or compositions for use in this aspect of the invention include those in which the therapeutic compound is retinol or a derivative or precursor thereof.Further preferred compositions include those compositions that contain or further contain at least one growth factor, at least one antibiotic, at least one antifungal compound or at least one antiviral compound. Suitable growth factors, antibiotics, antifungal compounds and antiviral compounds include those described herein and those known in dermatology and other related technical fields. According to this aspect of the invention, the conjugate or composition is suitably applied to or into the skin in a dosage sufficient to treat or prevent a skin disease, disorder or wound, and the condition of the skin in said human or veterinary subject is then monitored over time for improvement of the disease state or physical condition. Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml. In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation.If necessary, the conjugate or composition of the present invention is subsequently periodically re-administered to the skin or into the skin according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the skin disease, disorder or wound is healed, prevented or ameliorated. In such embodiments, the conjugate or composition of the present invention is suitably administered to the skin or into the skin topically, intraepidermally, intradermally or subcutaneously. Administration of the conjugate or composition to the skin or into the skin can be achieved by any known means, including in the form of a solution, an ointment, a salve, a patch, a cream, a topical administration solution and a drug-eluting wafer. For example, the conjugate or composition can be applied or introduced into the skin in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted into the skin, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition to one or more nanoparticles that are then delivered into the skin. Other suitable methods of applying the conjugate or composition to the skin or into the skin to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0478] Cancers that can be treated, prevented, improved or diagnosed using the compositions and methods of the present invention include, but are not limited to, skin cancer (e.g., skin cancers described elsewhere herein), intraluminal cancers and brain tumors.Intraluminal cancers that can be suitably treated, prevented, diagnosed or improved using the conjugates, compositions and methods of the present invention include, but are not limited to, colon cancer, intestinal cancer, duodenal cancer, gastric cancer, pancreatic cancer, esophageal cancer, bladder cancer (e.g., in situ non-muscle invasive bladder cancer or carcinoma of the bladder), cancer of the upper urinary tract, also known as the renal pelvis and also known to those skilled in the art as renal pelvis (e.g., upper tract urothelial carcinoma, Wilms' tumor and kidney cancer), vaginal cancer, cervical cancer, uterine cancer, ovarian cancer, luminal breast cancer and lung cancer.Brain tumors that can be suitably treated, prevented, diagnosed or improved using the conjugates, compositions and methods of the present invention include, but are not limited to, gliomas, glioblastomas, meningiomas, pituitary tumors, craniopharyngiomas and hemangioblastomas. The conjugates, compositions and methods of the invention are also suitably used to treat, prevent, diagnose or ameliorate other non-luminal cancers, including, but not limited to, prostate cancer, testicular cancer, non-luminal breast cancer, bone cancer, head and neck cancer, thyroid cancer, liver cancer, and sarcomas (e.g., Kaposi's sarcoma, Ewing's sarcoma, osteosarcoma, soft tissue sarcoma and rhabdomyosarcoma).

[0479] According to this aspect of the invention, a method of treating or preventing cancer in a human or veterinary subject suffering from or susceptible to cancer comprises administering the compositions described herein, particularly CMPs and CMPs and / or conjugates, to a human or veterinary subject in an organ lumen, or intracranially, or in or on the brain, at a site proximate to the location of the cancer or tumor. Without wishing to be bound by theory, the inventors speculate that in the area of ​​cancer, the CMP specifically targets the site of cancer and inserts into collagen structures, thereby directly modifying a functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, there is sufficient destruction of type I collagen, or, in the case of brain tumors, upregulation of type I collagen, such that the CMP and / or therapeutic compound are delivered to the site where they should act to treat, prevent or ameliorate cancer. Particularly preferred conjugates or compositions for use in this aspect of the invention include those conjugates or compositions, including those described herein, in which the therapeutic compound is a biotherapeutic compound, particularly one or more monoclonal antibodies or fragments thereof, or one or more therapeutic fusion proteins, particularly recombinant fusion proteins. Further preferred compositions include those compositions further comprising at least one growth factor, at least one antibiotic, at least one antifungal compound, or at least one antiviral compound. Suitable growth factors, antibiotics, antifungal compounds, and antiviral compounds include those described herein and those known in dermatology and other related technical fields. According to this aspect of the invention, the conjugate or composition is suitably applied to or within an organ lumen, or to the skull or brain, in a dosage sufficient to treat, prevent, or ameliorate cancer, and then the progression, remission, or stasis of cancer in said human or veterinary subject is monitored over time for improvement of the cancer disease state (e.g., tumor shrinkage, or cancer at least not progressing or in remission).Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml. In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically readministered into the organ lumen or intracranially, or into or onto the brain according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those of skill in the art, until the cancer is cured, prevented or ameliorated, or goes into permanent remission. In such embodiments, the conjugate or composition of the invention is suitably administered into the organ lumen or brain or into the organ lumen or brain parenterally, or by direct application to the tumor site, or, in the case of tumor removal or resection, by direct application to the tumor bed or wound following tumor removal or resection.Parenteral administration of the conjugates or compositions of the invention can be achieved via a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, transdermal diffusion, implantation of a drug-eluting wafer or film, sublingual, oral, aerosol inhalation, intravaginal, rectal, or intracranial. In certain such embodiments, the conjugates or compositions can be parenterally administered to a human or veterinary subject in the form of a mesh, film, wafer, sphere, nanoparticle, gel, or patch that is implanted within or at or near the site of a cancer. In other such embodiments, particularly those in which the cancer is an intraluminal cancer, the conjugates or compositions of the present invention can be administered to the lumen of an organ affected by cancer in a human or veterinary subject using a medical device suitable for that purpose, such as an endoscope, a bronchoscope (e.g., by bronchial lavage to treat, prevent or diagnose lung cancer, such as bronchial or lung cancer), a rectoscope, a colonoscope, a cystoscope (e.g., insertion into the bladder or upper urinary tract by cystoscopic irrigation), a gastroscope and a laparoscope, or other suitable surgical / medical device capable of delivering a dose of a medicament, such as the conjugates and compositions of the present invention, to the site of the cancer in a human or veterinary subject. In certain such embodiments, the conjugates or compositions can be administered after surgical removal or resection of a solid tumor, or removal or aspiration of tumor ascites, for example, using a trocar inserted into the abdomen to remove the ascites. In such embodiments, the conjugates or compositions of the present invention can be introduced directly into the surgical removal or ascites area (optionally with one or more additional therapeutic agents), for example, by any of the above-mentioned devices or instruments.

[0480] In other embodiments, administration of the conjugate or composition to the organ lumen or brain or in the organ lumen or brain can be achieved by any known means, including in the form of a solution, ointment, salve, patch, cream, topical application solution and drug-eluting wafer.For example, the conjugate or composition can be applied or introduced into the organ lumen or in the brain or on the brain in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in the organ lumen or brain, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition in one or more nanoparticles that are then delivered into the organ lumen or brain.Other suitable methods of applying the conjugate or composition to the organ lumen or brain or in the organ lumen or brain to achieve the therapeutic and diagnostic methods of the present invention will be readily understood by those skilled in the art.

[0481] Gastrointestinal diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include, but are not limited to, irritable bowel syndrome, Crohn's disease, ulcers, ulcerative colitis, esophagitis, Barrett's esophagitis, gastritis and proctitis.

[0482] According to this aspect of the invention, a method of treating or preventing a gastrointestinal disease or disorder in a human or veterinary subject suffering from or susceptible to a gastrointestinal disease or disorder comprises administering the compositions described herein, particularly CMPs and CMP-TC conjugates and compositions comprising said CMPs and / or conjugates, to a site in the gastrointestinal tract of a human or veterinary subject proximate to the location of a lesion associated with or causing the gastrointestinal disease or disorder. Without wishing to be bound by theory, the inventors hypothesize that in certain areas of gastrointestinal disease and disorders, sufficient disruption of type I collagen has occurred such that the CMP specifically targets the site of the gastrointestinal disease or disorder and, by inserting into the collagen structure, directly modifies the functional collagen matrix or, if the CMP is conjugated to a therapeutic compound, delivers the CMP and / or therapeutic compound to the site where they should act to treat, prevent or ameliorate the gastrointestinal disease or disorder. Particularly preferred conjugates or compositions for use in this aspect of the invention include those conjugates or compositions, including those described herein, in which the therapeutic compound is a biotherapeutic compound, particularly one or more monoclonal antibodies or fragments thereof, or one or more therapeutic fusion proteins, particularly recombinant fusion proteins. In accordance with this aspect of the invention, the conjugate or composition is suitably applied to or within the gastrointestinal tract in a dosage sufficient to treat, prevent or ameliorate a gastrointestinal disease or disorder, and then the progression, remission or stagnation of the gastrointestinal disease or disorder in a human or veterinary subject is monitored over time for improvement of the disease or disorder state. Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered into the gastrointestinal tract according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the gastrointestinal disease or disorder is cured, prevented or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically into the gastrointestinal tract or into the gastrointestinal tract. Parenteral administration is achieved via routes known in the art for administering therapeutic agents to the gastrointestinal tract, such as a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, transdermal diffusion, implantation of a drug-eluting wafer, sublingually, orally or rectally. In such methods, the composition is suitably administered parenterally to the human or veterinary subject in the form of a pill, capsule, liquid, suspension or powder to be ingested by the human or veterinary subject, or in the form of a mesh or patch to be implanted at or near the site of the disease or disorder in the gastrointestinal tract.In other such embodiments, particularly those in which the disease or disorder is within a lumen in the gastrointestinal tract, the conjugates or compositions of the invention can be administered to the lumen of the gastrointestinal tract in a human or veterinary subject using medical equipment suitable for that purpose, such as a rectoscope, colonoscope, cystoscope (e.g., for examination within the bladder or upper urinary tract), gastroscope, and laparoscope, or other suitable surgical / medical equipment capable of delivering a dose of a medicament, such as the conjugates and compositions of the invention, to the site of the gastrointestinal disease or disorder in a human or veterinary subject.

[0483] In other embodiments, administration of the conjugate or composition to or within the gastrointestinal tract can be achieved by any known means, including in the form of a solution, ointment, salve, patch, cream, topical application solution, and drug-eluting wafer.For example, the conjugate or composition can be applied or introduced to the gastrointestinal tract in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in the gastrointestinal tract, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition to one or more nanoparticles that are then delivered into the gastrointestinal tract.Other suitable methods of applying the conjugate or composition to or within the gastrointestinal tract to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0484] Genitourinary diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the present invention include, but are not limited to, female urinary incontinence, cystitis, interstitial cystitis, overactive bladder syndrome, ureteritis and vaginitis.

[0485] According to this aspect of the invention, a method of treating or preventing a urogenital disease or disorder in a human or veterinary subject suffering from or susceptible to a urogenital disease or disorder comprises administering the compositions described herein, particularly CMPs and CMP-TC conjugates and compositions comprising said CMPs and / or conjugates, to a site in the urogenital tract of a human or veterinary subject proximate to the location of a lesion that accompanies or causes the urogenital tract disease or disorder. Without wishing to be bound by theory, the inventors speculate that in the area of ​​certain urogenital diseases and disorders, sufficient disruption of type I collagen has occurred such that the CMP specifically targets the site of the urogenital disease or disorder and inserts into the collagen structure, thereby directly modifying a functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, delivering the CMP and / or therapeutic compound to the site where they should act to treat, prevent or ameliorate the urogenital disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably applied to or within the urogenital tract in a dosage sufficient to treat, prevent or ameliorate a urogenital disease or disorder, and then the progression, remission or congestion of the urogenital disease or disorder in a human or veterinary subject is monitored over time for improvement of the disease or disorder condition.Suitable dosages for such use are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered into the urogenital tract according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the urogenital disease or disorder is cured, prevented or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically into the urogenital tract or into the urogenital tract. Parenteral administration is achieved via any route known in the art for administering therapeutic agents to the gastrointestinal tract, such as a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, transdermal diffusion, implantation of a drug-eluting wafer, sublingually, orally, vaginally or rectally. In such methods, the composition is suitably administered parenterally to a human or veterinary subject in the form of a pill, capsule, liquid, suspension or powder that is ingested by the human or veterinary subject, or in the form of a mesh or patch that is implanted at or near the site of the disease or disorder in the urogenital tract.In other such embodiments, particularly those in which the disease or disorder is within a lumen in the gastrointestinal tract, the conjugates or compositions of the invention can be administered to the genitourinary lumen in a human or veterinary subject using medical devices suitable for that purpose, such as endoscopes, colposcopes and laparoscopes, or other suitable surgical / medical devices capable of delivering a dose of medicaments, such as the conjugates and compositions of the invention, to the site of the genitourinary disease or disorder in a human or veterinary subject.

[0486] In other embodiments, administration of the conjugate or composition into the urogenital tract or urogenital tract can be achieved by any known means, including in the form of a solution, ointment, salve, patch, wafer, film, gel, sphere, nanoparticle, cream, topical application solution, and drug-eluting wafer. For example, the conjugate or composition can be applied or introduced into the urogenital tract in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted into the urogenital tract, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition in one or more nanoparticles that are then delivered into the urogenital tract. Other suitable methods of applying the conjugate or composition into the urogenital tract or urogenital tract to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0487] Fibrotic diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include, but are not limited to, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, surgical scarring, systemic sclerosis, scleroderma, keloid formation and proliferative vitreoretinopathy.

[0488] According to this aspect of the invention, a method of treating or preventing a fibrotic disease or disorder in a human or veterinary subject suffering from or susceptible to a fibrotic disease or disorder comprises administering the compositions described herein, particularly CMPs and CMP-TC conjugates and compositions comprising said CMPs and / or conjugates, to a site in or near one or more tissues, organs or organ systems of a human or veterinary subject, proximate to the location of a fibrotic lesion that accompanies or causes the fibrotic disease or disorder. Without wishing to be bound by theory, the inventors speculate that in areas of certain fibrotic diseases and disorders, sufficient disruption of type I collagen has occurred such that the CMP specifically targets the site of the fibrotic disease or disorder and inserts into the collagen structure, thereby directly modifying a functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, delivering it to the site where the therapeutic compound should act to treat, prevent or ameliorate the fibrotic disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably applied to, near or within a tissue, organ or organ system in a dosage sufficient to treat, prevent or ameliorate a fibrotic disease or disorder, and the progression, remission or stagnation of the fibrotic disease or disorder in a human or veterinary subject is then monitored over time for improvement of the disease or disorder condition. Suitable dosages for such use are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered into, near, or on one or more tissues, organs, or organ systems according to the administration and treatment schedules and protocols described herein and well known to those skilled in the art, until the fibrotic disease or disorder is cured, prevented, or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically to, near, on, or in a tissue, organ, or organ system. Parenteral administration is achieved via routes known in the art for administering therapeutic agents to tissues, organs, or organ systems, such as via a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, endoscopic application, transdermal diffusion, implantation of a drug-eluting wafer, film, gel, or putty, sublingually, orally, or rectally. In the methods, the compositions are suitably administered parenterally to a human or veterinary subject in the form of a pill, capsule, liquid, suspension or powder that is ingested by the human or veterinary subject, or in the form of a mesh, film, wafer, gel, sphere, nanoparticle, putty or patch that is implanted at or near, on or within the site of a disease or disorder in a fibrous tissue, organ or organ system.

[0489] In other embodiments, administration of the conjugate or composition to, near, or in a tissue, organ, or organ system can be achieved by any known means, including in the form of a solution, ointment, salve, patch, film, gel, sphere, nanoparticle, putty, cream, topical solution, and drug-eluting wafer. For example, the conjugate or composition can be applied or introduced to, near, or in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in, near, or on the tissue, organ, or organ system, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition to, near, or in one or more nanoparticles that are then delivered in, near, or on the tissue, organ, or organ system. Other suitable methods of applying the conjugate or composition to, near, or in the tissue, organ, or organ system to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0490] Cardiovascular diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include, but are not limited to, myocardial infarction, heart failure, valvular heart disorders, atherosclerosis, cardiomyopathy, arrhythmias, congenital heart disease, coronary artery disease, pericardial disease, vascular occlusive disease (e.g., affecting the carotid arteries, aorta, renal arteries, femoral arteries, pulmonary arteries, and other large and small blood vessels, which may be arteries, arterioles, veins and venules, etc.), and Marfan syndrome.

[0491] According to this aspect of the invention, a method of treating or preventing a cardiovascular disease or disorder in a human or veterinary subject suffering from or susceptible to a cardiovascular disease or disorder comprises administering a composition as described herein, particularly a CMP and / or a CMP-TC conjugate and compositions comprising said CMP and / or conjugate, to the vascular system of a human or veterinary subject suffering from or susceptible to said disease or disorder. Without wishing to be bound by theory, the inventors speculate that in the area of ​​certain cardiovascular diseases and disorders, sufficient disruption of type I collagen occurs such that the CMP introduced into the vasculature of a subject specifically targets the site of the cardiovascular disease or disorder and, by inserting into collagen structures, directly modifies a functional collagen matrix or, if the CMP is conjugated to a therapeutic compound, delivers the CMP and / or therapeutic compound to the site where they should act to treat, prevent or ameliorate the cardiovascular disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably applied to the vascular system in a dosage sufficient to treat, prevent or ameliorate a cardiovascular disease or disorder, and then the progression, remission or stagnation of the cardiovascular disease or disorder in a human or veterinary subject is monitored over time for improvement of the disease or disorder condition.Suitable dosages for such use are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered to the vascular system according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the cardiovascular disease or disorder is cured, prevented or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically to or within the heart, pericardium, blood vessels or other relevant components of the vascular system. Parenteral administration is achieved via routes known in the art for administering therapeutic agents to the vascular system, such as via a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, transdermal diffusion, catheter insertion, embolization, implantation of a drug-eluting wafer or film, sublingually, orally or rectally. In the methods, the compositions are suitably administered parenterally to a human or veterinary subject in the form of a pill, capsule, liquid, suspension or powder that is ingested by the human or veterinary subject, or in the form of a mesh, wafer, film, gel, putty, sphere, nanoparticle or patch that is implanted at or near the site involved in the cardiovascular disease or disorder in the heart, pericardium, blood vessels or other relevant components of the vascular system.

[0492] In other embodiments, administration of the conjugate or composition to or within the vasculature can be accomplished by any known means, including in the form of a solution, ointment, salve, patch, film, gel, sphere, nanoparticle, cream, topical solution, and drug-eluting wafer. For example, the conjugate or composition can be applied or introduced to the heart, pericardium, blood vessel, or other relevant component of the vasculature in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in the heart, pericardium, blood vessel, or other relevant component of the vasculature, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition in one or more nanoparticles that are then delivered to the heart, pericardium, blood vessel, or other relevant component of the vasculature. Other suitable methods of applying the conjugate or composition to or within the vasculature to accomplish the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0493] Bone diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the present invention include, but are not limited to, osteoporosis, bone fractures, osteomyelitis, osteogenesis imperfecta, Paget's disease of bone, osteonecrosis, rickets, osteomalacia and acromegaly.

[0494] According to this aspect of the invention, a method of treating or preventing a bone disease or disorder in a human or veterinary subject suffering from or susceptible to a bone disease or disorder comprises administering the compositions described herein, particularly CMPs and CMP-TC conjugates and compositions comprising said CMPs and / or conjugates, to a site in or near one or more bones of a human or veterinary subject proximate to the location of a lesion that accompanies or causes the bone disease or disorder. Without wishing to be bound by theory, the inventors speculate that in areas of certain bone diseases and disorders, sufficient breakdown of type I collagen has occurred such that the CMP specifically targets the site of the bone disease or disorder and inserts into collagen structures, thereby directly modifying a functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, delivering them to the site where the therapeutic compound should act to treat, prevent or ameliorate the bone disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably applied to, near or into the bone in a dosage sufficient to treat, prevent or ameliorate a bone disease or disorder, and then the progression, remission or regression of the bone disease or disorder in a human or veterinary subject is monitored over time for improvement of the disease or disorder condition. Suitable dosages for such use are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered in, near, or on one or more bones according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the bone disease or disorder is cured, prevented, or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically to, near, on, or into the bone. Parenteral administration is achieved via routes known in the art for administering therapeutic agents to bone, such as a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, endoscopic application, transdermal diffusion, implantation of drug-eluting wafers, films, gels, or putties, sublingually, orally, or rectally. In such methods, the composition is suitably administered parenterally to the human or veterinary subject in the form of a pill, capsule, liquid, suspension, or powder that is ingested by the human or veterinary subject, or in the form of a mesh, film, wafer, gel, sphere, nanoparticle, putty, or patch that is implanted at, near, on, or in the site of the disease or disorder.

[0495] In other embodiments, administration of the conjugate or composition to or near the bone can be achieved by any known means, including in the form of a solution, ointment, salve, patch, film, gel, sphere, nanoparticle, putty, cream, topical solution, and drug-eluting wafer. For example, the conjugate or composition can be applied to or near the bone in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in, near, or on the bone, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition in one or more nanoparticles that are then delivered in, near, or on the bone. Other suitable methods of applying the conjugate or composition to or near the bone to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0496] Rheumatic diseases or disorders that can be treated, prevented, ameliorated or diagnosed using the compositions and methods of the invention include, but are not limited to, arthritis (particularly rheumatoid arthritis, osteoarthritis and psoriatic arthritis), bursitis, joint friction cramps, spondylosis, scleroderma, polymyalgia rheumatica and apicalthrombocytopenic syndrome.

[0497] According to this aspect of the invention, a method of treating or preventing a rheumatic disease or disorder in a human or veterinary subject suffering from or susceptible to a rheumatic disease or disorder comprises administering a composition as described herein, particularly a CMP or CMP-TC conjugate and compositions comprising said CMP and / or conjugate, to a site in the human or veterinary subject proximate to the location of a lesion that accompanies or causes the rheumatic disease or disorder. Without wishing to be bound by theory, the inventors speculate that in certain areas of rheumatic disease and disorder, sufficient disruption of type I collagen has occurred such that the CMP specifically targets the site of the rheumatic disease or disorder and inserts into the collagen structure, thereby directly modifying the functional collagen matrix, or, if the CMP is conjugated to a therapeutic compound, delivering them to the site where the therapeutic compound should act to treat, prevent or ameliorate the rheumatic disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably administered to or within a human or veterinary subject in a dosage sufficient to treat, prevent or ameliorate a rheumatic disease or disorder, and the progression, remission or regression of the rheumatic disease or disorder in the human or veterinary subject is then monitored over time for improvement of the disease or disorder condition. Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically readministered to the human or veterinary subject according to the administration and treatment schedules and protocols described herein and other administration and treatment schedules and protocols well known to those skilled in the art until the rheumatic disease or disorder is cured, prevented or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically to or within a human or veterinary subject. Parenteral administration is achieved via a route known in the art for administering therapeutic agents designed to treat, prevent or ameliorate a rheumatic disease or disorder, such as a route selected from the group consisting of subcutaneous injection, intravenous infusion, intra-arterial infusion, transdermal diffusion, implantation of a drug-eluting wafer, sublingually, orally, vaginally or rectally. In such methods, the composition is suitably administered parenterally to the human or veterinary subject in the form of a pill, capsule, liquid, suspension or powder to be ingested by the human or veterinary subject, or in the form of a mesh or patch to be implanted at or near the site of the disease or disorder in the human or veterinary subject.In other such embodiments, particularly those in which the rheumatic disease or disorder is located at or near bone, tendons, cartilage, ligaments, capsules, joints or related structures, the compositions or conjugates of the invention are suitably administered to a human or veterinary subject using a medical device suitable for that purpose, for example, a laparoscope, or other suitable surgical / medical device capable of delivering a dose of medicaments, such as the conjugates and compositions of the invention, to the site of the genitourinary disease or disorder in a human or veterinary subject.

[0498] In other embodiments, administration of the conjugate or composition to or within a human or veterinary subject can be accomplished by any known means, including in the form of a solution, ointment, salve, patch, cream, topical solution, and drug-eluting wafer. For example, the conjugate or composition can be administered to or introduced into the human or veterinary subject in the form of one or more droplets of a solution or suspension containing the composition or conjugate, or by injection, or in the form of a coating on a solid material that is implanted in the human or veterinary subject, or in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition in one or more nanoparticles that are then delivered into the human or veterinary subject. Other suitable methods of administering the conjugate or composition to or within a human or veterinary subject to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0499] Diseases or disorders of the nervous system or nervous system (including the central nervous system ("CNS") and peripheral nervous system ("PNS")) that can be treated, prevented, ameliorated, or diagnosed using the compositions and methods of the invention include diseases or disorders of one or more nerves or nerve processes (including axons, dendrites and neurons or neuronal bodies, ganglia, nerve bundles, etc.) that affect the nervous system. Neurodegeneration (in many different physiological or disease contexts, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, traumatic encephalopathy, non-Alzheimer's dementia, encephalitis and meningitis), disorders involving the peripheral nerves (such as diabetic peripheral neuropathy, nutritional neuropathy and alcohol-induced neuropathy), glaucoma, macular degeneration (wet and / or dry, which may or may not be age-related), neurotrophic keratitis, retinopathies (which may include diabetic retinopathy, ischemic retinopathy, proliferative retinopathy, and other genetic retinopathies and genetic retinal diseases or disorders known in the art), neuropathies (neuropathy or These include, but are not limited to, certain ocular nerve diseases and disorders, including those involving or affecting the corneal, retinal and optic nerves, including, but not limited to, injury or inflammation of one or more corneal nerves (which may result from transection of nerve processes, or injury or inflammation of the eye due to external disease or trauma / wound, including crush or twisting injury), corneal pain (which may be acute or chronic and may result from corneal nerve injury or injury or corneal denervation, such as, for example, periocular pain, extraocular pain and post-herpetic neuralgia), and encephalopathy (e.g., traumatic encephalopathy such as concussion, encephalitis and meningitis). In certain such embodiments, the compositions and methods of the present invention may be used to induce nerve repair or regrowth (e.g., by nerve regeneration) in cranial nerves, including, but not limited to, the optic nerve, retinal nerve, auditory nerve or spinal nerve.In other such embodiments, the compositions and methods of the present invention can be used for protection of certain nerves against degeneration or further or continuing degeneration (i.e., providing a neuroprotective function), which may be useful for preventing, reducing or slowing the progression of peripheral nerve degeneration to prevent and / or treat diabetic peripheral neuropathy, nutritional neuropathy and alcohol-induced peripheral neuropathy, as well as preventing, reducing or slowing the progression of corneal, optic and / or retinal nerves to prevent and / or treat corneal pain (e.g., acute or chronic corneal pain, including, but not limited to, periocular pain, extraocular pain and post-herpetic neuralgia), glaucoma, genetic retinal diseases or disorders and genetic retinopathies (e.g., diabetic retinopathy). Other beneficial applications of the compositions and methods of the present invention in the treatment, prevention, amelioration or diagnosis of nerve and nervous system diseases or disorders will be understood by those skilled in the art based on the description provided herein, together with information readily available in the art.

[0500] According to this aspect of the invention, a method of treating or preventing a neurological or nervous system disease or disorder in a human or veterinary subject suffering from or susceptible to a neurological or nervous system disease or disorder comprises administering compositions as described herein, particularly CMPs and CMP-TC conjugates and compositions comprising said CMPs and / or conjugates, to a site in or near one or more tissues, organs or organ systems of a human or veterinary subject proximate to the location of a neurological or nervous system lesion that accompanies or causes a neurological or nervous system disease or disorder. Without wishing to be bound by theory, the inventors speculate that in the area of ​​a neurological or nervous system disease or disorder, there has been sufficient disruption of type I collagen (perhaps among other components of the local extracellular matrix) such that the CMP specifically targets the site of the neurological or nervous system disease or disorder and, by inserting into the collagen structure, directly induces neuroregeneration and / or neuroprotection via modification of the functional collagen matrix, or, if the CMP carries a therapeutic compound, delivers it to the site where the therapeutic compound should act to treat, prevent or ameliorate the neurological or nervous system disease or disorder. According to this aspect of the invention, the conjugate or composition is suitably applied to, near or within a tissue, organ or organ system in a dosage sufficient to treat, prevent or ameliorate a neurological or nervous system disease or disorder, and the progression, remission or retardation of the neurological or nervous system disease or disorder in a human or veterinary subject is then monitored over time for improvement of the disease or disorder state. Suitable dosages for such uses are concentrations of about 10ng / ml to about 500ng / ml, about 15ng / ml to about 400ng / ml, about 20ng / ml to about 300ng / ml, about 25ng / ml to about 250ng / ml, about 30ng / ml to about 200ng / ml, about 35ng / ml to about 200ng / ml, about 40ng / ml to about 200ng / ml, about 50ng / ml to about 200ng / ml, about 75ng / ml to about 200ng / ml and about 100ng / ml to about 200ng / ml.In certain such embodiments, the conjugate or composition is suitably applied to the eye at a dose of about 25 ng / ml to about 500 ng / ml, e.g., about 25 ng / ml, about 30 ng / ml, about 35 ng / ml, about 40 ng / ml, about 45 ng / ml, about 50 ng / ml, about 75 ng / ml, about 100 ng / ml, about 125 ng / ml, about 150 ng / ml, about 175 ng / ml, about 200 ng / ml, about 225 ng / ml, about 250 ng / ml, about 300 ng / ml, about 350 ng / ml, about 400 ng / ml, about 450 ng / ml or about 500 ng / ml. Further concentrations and amounts of the conjugate or composition of the invention suitable for use in such methods can be readily determined by one of skill in the art based on the information contained herein and available in the art without resorting to undue experimentation. If necessary, the conjugate or composition of the invention is subsequently periodically re-administered into, near, or on one or more tissues, organs, or organ systems according to the administration and treatment schedules and protocols described herein and well known to those skilled in the art, until the neurological or nervous system disease or disorder is cured, prevented, or ameliorated. In such embodiments, the conjugate or composition of the invention is suitably administered parenterally or topically to, near, on, or in a tissue, organ, or organ system. Parenteral administration is achieved via any route known in the art for administering therapeutic agents to a tissue, organ, or organ system, such as a route selected from the group consisting of subcutaneous injection, intradermal injection, intramuscular injection, intracranial injection, intrathecal injection, or injection into any tissue, organ, or organ system in which a neurological or nervous system disease or disorder is found, intravenous injection, intraarterial injection, endoscopic application, transdermal diffusion, implantation of a drug-eluting wafer, film, gel, or putty, sublingual, oral, or rectal.In certain such methods, the compositions are suitably administered parenterally to a human or veterinary subject in the form of an injectable solution or paste, pill, capsule, liquid, suspension or powder that is inhaled or ingested by the human or veterinary subject, or in the form of a mesh, film, wafer, gel, sphere, nanoparticle, paste, putty or patch that is implanted near a tissue, organ or organ system, or on or in the vicinity of the site of a nerve or nervous system disease or disorder. In certain such embodiments, one or more of the compounds, compositions or conjugates of the invention may be coated onto or into a mesh or "sleeve" material such that one or more of the compounds, compositions or compositions of the invention are impregnated into the mesh or sleeve material, and the mesh or sleeve may then be applied to an injured (e.g., severed) or damaged nerve, neurite or nerve bundle.

[0501] In other embodiments, administration of the conjugate or composition to or near or in a tissue, organ or organ system can be achieved by any known means, including in the form of a solution, ointment, salve, patch, film, gel, paste, sphere, nanoparticle, putty, cream, topical solution and drug-eluting wafer. For example, the conjugate or composition can be applied or introduced to or near a tissue, organ or organ system in the form of one or more droplets of a solution or suspension containing the composition or conjugate (e.g., in the form of a topical ocular drop for use in the fundus), by injection, in the form of a coating on a solid material that is implanted in, near or on the tissue, organ or organ system, in the form of a mesh or patch, or by adhering or encapsulating the conjugate or composition to or near one or more nanoparticles that are then delivered in, near or on the tissue, organ or organ system. Other suitable methods of applying the conjugate or composition to or near or in a tissue, organ or organ system to achieve the therapeutic and diagnostic methods of the present invention will be readily apparent to those skilled in the art.

[0502] In related embodiments, the present invention provides devices, particularly medical devices, suitable for treating or preventing a disease, disorder or condition in a human or veterinary subject suffering from or susceptible to said disease, disorder or condition. The device suitably comprises at least one of the compositions of the present invention in the form of a coating on the device or a composition embedded within the device such that the composition is released or eluted from the device upon implantation within the body of the human or veterinary subject. Suitable such devices include, but are not limited to, artificial joints, stents, catheters, sutures, bone screws, bone plates, prosthetic devices (e.g., artificial limbs, artificial body structures, artificial organs, etc.), absorbable or non-absorbable meshes, absorbable or non-absorbable patches, drug-releasing wafers, brain neurostimulators (e.g., deep brain neurostimulators), gastric stimulators, cochlear implants, defibrillators, cardiac pacemakers, insulin pumps, and internal infusion pumps. Other suitable devices useful in accordance with this aspect of the present invention will be readily apparent to those of skill in the art.

[0503] The devices provided by this aspect of the invention are useful for treating, preventing or ameliorating a disease, disorder or condition in a human or veterinary subject suffering from or susceptible to said disease, disorder or condition. In a method according to this aspect, one or more medical devices of the invention are implanted into a human or veterinary subject and the condition of the human or veterinary subject is monitored until the disease, disorder or condition is cured, ameliorated or prevented in the human or veterinary subject. Suitable diseases, disorders and conditions which may be cured, treated, ameliorated or prevented using the devices and methods of the invention include cancer (such as those described elsewhere herein), as well as diseases, disorders and conditions of the integumentary system (particularly diseases or disorders of the skin, such as those diseases or disorders detailed herein), the muscular system, the skeletal system (particularly diseases or disorders of the bones, joints, cartilage, tendons or ligaments, such as those diseases or disorders detailed herein), the nervous system (particularly diseases and disorders of the brain or the nervous system of the eye (including but not limited to diseases and disorders involving the corneal nerves, such as diseases and disorders resulting from injury or damage to the corneal nerves or denervation, e.g. corneal pain (which may be acute or chronic), including but not limited to diseases and disorders resulting from periocular pain, extraocular pain and post-herpetic neuralgia)), glaucoma, cataracts, vitreous adhesions or floaters, macular degeneration, dry eye syndrome, corneal corneal ulcer, noninfectious corneal ulcer, noninfectious corneal melt, infectious corneal ulcer, infectious corneal melt, conjunctivitis, Stevens-Johnson syndrome, scleritis, episcleritis, iritis, uveitis, vitritis, Behçet's disease uveitis, birdshot retinochoroidopathy, juvenile idiopathic arthritis (JIA)-associated uveitis, multifocal choroiditis with panuveitis, necrotizing scleritis, serpiginous choroidopathy, sympathetic ophthalmia, Vogt-Koyanagi-Harada (VKH) disease, noninfectious panuveitis , ectasia, keratoconus, corneal lacerations, corneal erosions, corneal abrasions, and post-cataract surgery conditions requiring medication, or post-glaucoma surgery conditions requiring medication, or posterior ocular disorders, such as macular degeneration (wet, dry and age-related), retinitis pigmentosa, retinal tears or detachments, retinopathy (e.g., diabetic retinopathy), retinal artery or vein occlusion (e.g., BRAO (branch retinal artery occlusion), CRAO (central retinal artery occlusion),BRVO (branch retinal vein occlusion), CRVO (central retinal vein occlusion)), and ocular disorders involving the retina, retinal epithelium (particularly the retinal pigment epithelium), retinal blood vessels, retinal nerve or optic nerve, including but not limited to optic neuritis, optic neuropathies (including, for example, AION (anterior ischemic optic neuropathy), traumatic optic neuropathy), and optic atrophy (for example glaucomatous optic atrophy), as well as other neurological disorders affecting the eye or periocular area, including periocular and extraocular diseases, disorders and conditions such as cranial nerve palsies, including but not limited to cranial nerve palsies 3, 4, 5 (e.g. trigeminal neuralgia and posterior herpetic neuralgia), 6 and 7 (e.g. Bell's palsy), circulatory system, lymphatic system, respiratory system (diseases or disorders affecting the epiglottis, trachea, bronchi, bronchioles or lungs of human or veterinary subjects) , including in particular those diseases and disorders detailed herein), the endocrine system, the urinary / excretory system (including diseases or disorders affecting the kidneys, ureters, bladder, upper urinary tract (i.e. renal pelvis), ureters or urethra of a human or veterinary subject, in particular those diseases and disorders detailed herein), the reproductive system (including diseases and disorders affecting the testes, prostate, penis, vagina, cervix, uterus, fallopian tubes or ovaries of said human or veterinary subject, in particular those diseases and disorders detailed herein), the digestive system (including diseases or disorders affecting the esophagus, stomach, small intestine, colon or rectum of said human or veterinary subject, in particular those diseases and disorders detailed herein), and the nervous or nervous system (including the peripheral nervous system and the central nervous system, in particular those nervous or nervous system disorders, diseases and injuries detailed herein). Suitable methods for implanting one or more of the devices provided by this aspect of the invention into a human or veterinary subject to effect the treatment, prevention, amelioration or diagnosis of a disease, disorder or medical or physical condition in a human or veterinary subject will be well known to those skilled in the relevant medical and surgical arts.

[0504] Concentrations of CMP or CMP-TC conjugates useful for treating, preventing, ameliorating or diagnosing one or more diseases or disorders by the methods of the present invention are readily understood by those skilled in the pharmaceutical and medical arts. For unconjugated CMPs, suitable amounts or concentrations of CMP administered to a subject, particularly a human or veterinary subject, suitable amounts or concentrations of CMP used include those described herein. Those skilled in the medical, pharmaceutical and / or pharmacological arts can determine the appropriate amount of the conjugates and compositions of the present invention to be used per kilogram (kg) of body weight of a human or veterinary subject based on the explanations provided herein. For conjugated CMP-TCs, the amount of active pharmaceutical ingredient or biologic is calculated throughout the conjugation process such that an amount or concentration of CMP similar to those described herein, both in concentration (e.g., ng / ml or μg / ml) and amount (e.g., mg per kg body weight), is suitably administered to a subject to deliver a medicamentically effective amount of the desired active pharmaceutical ingredient or biologic depending on the disease or disorder to be treated, prevented, ameliorated or diagnosed in a human or veterinary subject. Suitable amounts or concentrations of active pharmaceutical ingredients or biologics to be used in accordance with this aspect of the invention will be well known to those of skill in the art and can be readily determined from the information contained herein, as well as other information available in the art.

[0505] Those skilled in the art will readily appreciate that other suitable changes and modifications may be made to the methods and applications described herein without departing from the scope of the invention or any of its embodiments. Having described the invention in detail, it will be more clearly understood by reference to the following embodiments, which are included herein for purposes of illustration only and are not intended to be limiting of the invention. Working Example EXAMPLES

[0506] Effect of CMP and CMP-TC conjugates on mouse corneal epithelial healing in vivo

[0507] To investigate the potential therapeutic effects of the CMPs and CMP-TC conjugates of the present invention, a study was designed to test certain CMPs and CMP-TC conjugates in an in vivo setting, i.e., in healing the corneal epithelium of wounded mouse eyes. Female mice (8-week-old C57BL / 6, 7 mice per test subject) were anesthetized and the cornea of ​​the mouse eye was injured to inflict a 1.5 mm superficial epithelial wound deep enough to expose the anterior stroma, thereby damaging and exposing the collagen matrix. The wound was created by a punch followed by an Algerbrish scraping technique (see Carlson, E., et al., "Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model," J. Ocular Pharmacol. Ther., published online February 2, 2018, accessed at https: / / doi.org / 10.1089 / jop.2017.0080). After wounding, corneas were treated with CMP or CMP-TC conjugates at 25 nM (approximately 3 mg / kg) in PBS water. Negative control mice were treated with vehicle (PBS) alone, and positive control mice were treated with 100 ng / mL epidermal growth factor (EGF). Wound size at various time points over 48 hours was examined by fluorescein staining (Carlson et al., supra), and fluorescent micrographs were taken and quantified using Image J software (see Rush, JS et al., Investig. Ophthalmol. Visual Sci. 57(14):5864-5871 (2016); Rush, JS et al., Investig. Ophthalmol. Visual Sci. 55(8):4691-4699 (2014)). The results are shown in Figure 1.

[0508] FIG. 1 shows that the CMP and CMP-TC conjugates of the invention significantly accelerated re-epithelialization and sub-epithelial stromal healing in the cornea of ​​mouse eyes compared to both EGF and vehicle. FIGS. 1a-1d show the wound size (visualized as a circle of fluorescein fluorescence in each photomicrograph) immediately after wound induction, and FIGS. 1e-1h show the wound size 16 hours after wounding and treatment with various test substances. FIGS. 1a and 1e correspond to PBS (negative control), FIGS. 1b and 1f correspond to EGF (positive control), FIGS. 1c and 1g correspond to "compound 3," i.e., the (Pro-Pro-Gly)7CMP of the invention (SEQ ID NO: 1), and FIGS. 1d and 1h correspond to "compound 10," i.e., the (Hyp-Pro-Gly)7CMP-P substance conjugate of the invention (SEQ ID NO: 391). The results demonstrate that both CMPs of the present invention (compounds 3 and 10) showed significant acceleration of wound healing in mouse cornea and corneal stroma within 16 hours of treatment (as indicated by a decrease in diameter and reduced intensity of fluorescence) compared to both PBS and EGF, which showed lower levels of healing.

[0509] To examine corneal wound healing at the histological level, mice were sacrificed 24 hours after wounding and treatment with PBS or Compound 3 as described above, eyes were removed, fixed in formalin, sectioned, and sections were stained with H&E and examined by light microscopy. Results from these experiments confirmed that within 24 hours after wounding and treatment with Compound 3 (Figure 1j), the corneal epithelium showed substantial healing (formation of an intact epithelial layer, as well as significantly reduced edema and collapse of the subepithelial stroma) compared to corneal epithelial sections taken from eyes of mice treated with PBS only (Figure 1i). Confirming these results at higher magnification (Figure 2), corneal sections from eyes of mice treated with PBS (Figure 2a) showed substantial destruction of the subepithelial matrix and lack of basement membrane (arrows). In contrast, corneal sections from mouse eyes treated with compound 3, a CMP of the present invention (FIG. 2b), showed a healing cornea as indicated by an intact epithelial layer with a modified basement membrane (arrows), along with significantly reduced edema and disruption of the subepithelial matrix. To determine the extent of healing, sections prepared as in FIG. 2 were examined microscopically and the average length of attachment of the epithelial layer to the basement membrane and subepithelial stroma was measured. The results of these analyses are shown in FIG. 3, which shows that within 24 hours of treatment with 250 nM compound 3, a CMP of the present invention, the corneal wound was almost completely healed (compared to intact, i.e., unwounded eye sections). In contrast, lower concentrations of compound 3 were less effective at inducing healing, but were better in terms of healing when compared to compound 10, which showed results similar to those seen with EGF and PBS.

[0510] Taken together, the results in Figures 1-3 support the use of the CMP and CMP-TC conjugates of the invention to promote corneal wound healing and stromal collagen repair in injured mouse eyes, which are models of a variety of ocular conditions in human and veterinary subjects, including dry eye of various etiologies and corneal lacerations or ulcers. EXAMPLES

[0511] Effect of CMP on proliferation and migration of retinal pigment epithelial cells To investigate the potential therapeutic effects of the CMPs and CMP-TC conjugates of the present invention in ocular fundus conditions, a study was designed to test certain CMPs and CMP-TC conjugates in an in vitro setting, namely, in retinal pigment epithelial (RPE) cell proliferation and migration. ARPE19 cells, a human RPE cell line expressing markers of differentiated RPE cells (see Dunn, KC, et al., Exp. Eye Res. 62(2):155-170 (1996)), were obtained from ATCC (Manassas, VA). Cells (100,000 cells / ml in 2 ml per well) were seeded onto 100 mm collagen-coated tissue culture plates (coated with 100 μg / ml type I collagen (Advanced BioMatrix) for 2 hours at 37°C) pretreated with collagenase (Worthington Biochemical Corporation, 100 U / ml in TNC buffer) and then treated with 100 μM compound 3 ((Pro-Pro-Gly)7CMP of the present invention, SEQ ID NO: 1) in TNC buffer or vehicle as a negative control. Plates were incubated overnight at 37°C and then assessed by phase contrast microscopy for density, morphology and network formation. Representative results are shown in Figure 4.

[0512] FIG. 4 shows that the CMP and CMP-TC conjugate of the present invention significantly accelerated the proliferation and network formation of RPE cells compared to vehicle. FIG. 4a shows RPE cells seeded on collagen-coated plates treated with collagenase followed by vehicle only (negative control), and FIG. 4b shows the results when cells were seeded on plates treated with the CMP of the present invention (compound 3). The results show that compound 3 induced a significant acceleration of proliferation (i.e., higher cell density in monolayer), spreading, migration, and network formation between adjacent RPE cells (FIG. 4b) compared to cells on vehicle-treated plates (FIG. 4a), which had fewer cells, less spreading on the plate, and weaker network formation between adjacent cells. These results suggest that the CMP of the present invention (i.e., compound 3) promotes proliferation, migration, and network formation of RPE cells in vitro.

[0513] To examine the effect of the CMP of the present invention on the underlying collagen matrix in the experiment shown in Figure 4, collagenase-treated collagen-coated plates (prepared as outlined above) were examined by differential interference contrast (DIC) microscopy. As shown in Figure 5, high magnification DIC micrographs demonstrated that the underlying collagen matrix on vehicle-treated plates (Figure 5a) formed randomly oriented collagen fibers (arrows), whereas compound 3 (Figure 5b) formed fibers exhibiting a parallel arrangement (arrows) similar to that observed in the interstitial matrix of endogenous tissue in the absence of injury. These results for compound 3 are similar to those reported in other in vitro systems (Kivanany, PB et al., J. Funct. Biomater. 9(4):54 (2018); Hapach, LA et al., Phys. Biol. 12(6): 061002 (2015); Lanfer, B. et al, Biomaterials 29:3888-3895 (2008); Saeidi, N et al., Biomaterials 30:6581-6592 (2009)).

[0514] Based on the results shown in FIG. 5 and similar reports in the literature, the degree of parallel (i.e., unidirectional) orientation of collagen observed in plates treated with the CMP of the present invention (compound 3) was quantified by digital analysis of the photomicrographs shown in FIG. 5 according to an algorithm recently reported in the literature (Cooper, ML et al., Acta Neuropathol. Commun. 6(1):38 (2018)). The results of this analysis (FIG. 6) showed that treatment of collagenase-treated collagen-coated plates with compound 3 improved collagen parallel alignment by approximately three-fold compared to that observed on vehicle-treated plates. Taken together with the results shown in FIG. 5, these results demonstrate that the CMP of the present invention (i.e., compound 3) was able to rapidly induce the formation of organized collagen fibers in an in vitro matrix similar to that observed in intact and healed tissue in vivo.

[0515] To examine the potential of the CMP of the present invention to promote proliferation of RPE cells, ARPE19 cells cultured on collagenase-treated collagen-coated plates as described above were examined by phase contrast microscopy for density on the plate surface. The plates were divided into a grid of set unit area (15 μm × 15 μm) and the number of cell nuclei was measured for vehicle-treated and CMP (compound 3)-treated plates. As shown in Figure 7, RPE cells cultured on CMP-treated plates (Figure 7b) were significantly more numerous per unit plate area than cells on vehicle-treated plates (Figure 7a). These results indicate that compound 3 promotes proliferation of RPE cells in vitro.

[0516] As a model for RPE cell migration and adhesion occurring in certain ocular diseases (e.g., macular degeneration and retinitis pigmentosa) and in the healing of retinal injuries, the CMPs of the present invention were also examined for their ability to induce RPE cell migration and adhesion in in vitro assays. Transwell insert membranes (Costar, 8 μm pore size) were coated with 500 μL of substrate (100 μg / ml human type I collagen or 100 μg / ml compound 3) or soaked in medium (water) overnight at room temperature. After 24 hours, the insert membranes were washed three times with PBS and dried at 37°C. Approximately 105 ARPE19 cells for each condition were resuspended in 100 μL of serum-free medium and added to the apical side of the insert membrane. The inserts were then placed into 24-well plates containing 0.5 mL of complete medium (plus 10% FBS), which attracts cells and promotes migration, and the plates were incubated at 37°C for 4 hours. We then assessed to what extent the membrane coating allows cell migration and promotes their adhesion to the bottom side of the membrane. Following incubation, non-migrating cells on the top of the insert were carefully removed with a cotton swab. Cells that adhered to the bottom side of the membrane after migration were fixed with 4% paraformaldehyde for 5 min at room temperature, stained with 0.1% crystal violet solution for 5 min, and then gently washed with water. The number of cells migrating and adhering to the bottom side of the coated membrane under the various conditions described above was then measured by counting cells by microscopy in 10x and 20x fields of view, with 6 fields per membrane insert. All experiments were performed in duplicate. Qualitative results (Figure 8) demonstrated that in membranes treated with the CMP of the present invention, i.e., compound 3, more RPE cells migrated through the membrane and adhered to the bottom side of the membrane (Figure 8c) compared to both vehicle (Figure 8a) and native collagen (Figure 8b). These qualitative results were also supported quantitatively, where compound 3 was found to significantly increase RPE cell migration and adhesion compared to both vehicle and native collagen (Figure 9).

[0517] In a related experiment to examine cell migration, only the apical surface of the transwell membrane was coated with vehicle, native human type I collagen (100 μg / mL) or compound 3 (200 μM) (in a 50 μL solution). Other conditions were the same as above. The results of this experiment (FIG. 10) demonstrated that compound 3 significantly increased membrane migration of RPE cells compared to native type I collagen. Vehicle and compound 3 were equally effective in enabling migration, indicating that compound 3 provides a substrate for RPE cell migration without the barrier to migration provided by native collagen. These results demonstrate that the CMPs of the present invention, particularly compound 3, induce RPE cell migration and adhesion in vitro and provide a useful model of RPE cell migration and adhesion in vivo in areas of collagen damage accompanied by disruption of the retinal epithelium.

[0518] Taken together, these results support the use of the CMP and CMP-TC conjugates of the invention to promote retinal epithelial healing and stromal collagen repair in mammalian retinal epithelial cell lines in models of a variety of ocular fundus conditions in human and veterinary subjects, including macular degeneration (dry, wet and age-related), retinitis pigmentosa, and other ocular disorders, diseases, injuries and conditions involving the retinal epithelium. EXAMPLES

[0519] Effect of CMP on the adhesion of retinal pigment epithelial cells to disrupted collagen matrices The inventors sought to further explore the potential therapeutic efficacy of the CMPs and CMP-TC conjugates of the present invention in ocular fundus conditions, particularly those in which the collagen matrix may be destroyed. Thus, studies were designed to test certain CMPs and CMP-TC conjugates in an in vitro setting, i.e., in the in vitro adhesion of retinal pigment epithelial (RPE) cells to tissue culture plates coated with collagen, treated with a collagen-destroying enzyme, and then treated with the CMPs of the present invention, as an in vivo model of a matrix that may be destroyed and then repaired.

[0520] To test the ability of the selected enzyme (matrix metalloproteinase-1 (MMP-1)) to digest collagen used in the in vitro assay, 60 nM MMP-1 was activated with 2 mM APMA in TNC buffer for 30 min at 37 °C. Human type I atelocollagen (3.375 μg, 0.2 μg / μl) was then added to the reaction and allowed to digest for an additional 6 h at 37 °C. The reaction was then subjected to SDS-PAGE under reducing conditions. The results are shown in Figure 11. As can be seen in Figure 11A, the α1 and α2 components of type I collagen were resolved in the gel and treatment of collagen with MMP-1 (to form "cleaved collagen") significantly digested these components into lower molecular weight fragments (TCs). A and T.C. B ) as shown in FIG. 11B. Quantification of digestion normalized to the α1 and α2 bands shown in the undigested collagen sample demonstrated that treatment of collagen with MMP-1 reduced the overall length of these chains by approximately 7.4-fold (>80% reduction). These results demonstrate the collagen cleavage ability of MMP-1 when used in the in vitro assay of this example. These results are consistent with previous reports that MMP-1 unwinds triple helical type I collagen prior to enzymatic hydrolysis of peptide bonds (see Chung L. et al., EMBO J. 23(15):3020-3030 (2004)).

[0521] For the cell assay, ARPE19 cells (see Example 2) were seeded on tissue culture plates coated with intact collagen or MMP-1 digested collagen. MMP-1 was activated using APMA as described above. To test "cleaved collagen", human type I atelocollagen was digested with activated MMP-1 as described above, and then tissue culture plates were coated overnight with intact human type I atelocollagen or cleaved collagen. Plates were then treated with vehicle (PBS) or one of four different CMPs of the invention, namely CMP A (SEQ ID NO: 3), CMP B (SEQ ID NO: 6), CMP C (SEQ ID NO: 391) or CMP D (SEQ ID NO: 13), at 100 μM each, i.e. 100 μL per well, and incubated at 37° C. for 5 hours. Plates were then washed with medium, and ARPE-19 cells were seeded evenly on plates with one of the following three surface coating conditions: (1) Intact collagen, (2) Cleaved collagen, and (3) Cleaved collagen + CMP. The plates were then incubated at 37° C. for 19 hours and then examined for cell attachment by phase contrast microscopy. Representative results are shown in FIGS. 12 and 13.

[0522] FIG. 12 shows that RPE cells attached very readily to collagen-coated plates (FIG. 12A), but less well to cleaved collagen-coated plates (FIG. 12B). However, it was observed that certain CMPs of the present invention were able to repair the collagen matrix on the plates to such an extent that RPE cells showed enhanced adhesion at a level higher than that seen on cleaved collagen plates. For example, in photomicrographs, cells seeded on cleaved collagen-coated plates treated with CMP B (SEQ ID NO: 6) showed enhanced adhesion compared to cleaved collagen plates (FIG. 12D). However, as seen in FIG. 12C, this tendency to enhanced adhesion was less pronounced on cleaved collagen-coated plates and plates treated with CMP A (SEQ ID NO: 3). Quantitative assays of cell adhesion on cut collagen plates treated with four different CMPs supported these results (Figures 13A and 13B) in that both CMP B and CMP D (SEQ ID NO: 13) significantly enhanced adhesion compared to cut collagen and CMP A and CMP C (SEQ ID NO: 391), presumably enhancing the ability to repair digested collagen matrix on plates. These results provide a cell-based correlation with the DIC microscopy results of Example 2, which demonstrated the effect of CMP treatment on the remodeling of disrupted collagen matrix in vitro, and suggest that certain CMPs of the invention may be useful in promoting the adhesion, proliferation, migration and network formation of RPE cells, and possibly neural cells in general, in vitro by enhancing the repair of disrupted collagen matrix. EXAMPLES

[0523] Effect of CMP on neurite outgrowth of dorsal root ganglion cells in vitro The inventors sought to further explore the potential therapeutic effects of the CMPs and CMP-TC conjugates of the present invention in neuronal and nervous system conditions, particularly those in which the collagen matrix may be destroyed. Therefore, studies were designed to test specific CMPs and CMP-TC conjugates in another in vitro setting, namely in dorsal root ganglion (DRG) neuron survival and neurite outgrowth in vitro.

[0524] In these assays, DRG neurons were isolated from 19-day-old rat fetuses and plated onto tissue culture plates coated with intact collagen or MMP-1-digested collagen, then treated with vehicle (PBS) or one of four different CMPs, namely CMP A (SEQ ID NO: 3), CMP B (SEQ ID NO: 6), CMP C (SEQ ID NO: 391) or CMP D (SEQ ID NO: 13), at 100 μM, i.e., 100 μL per well, respectively, and incubated at 37° C. for 5 hours. The plates were then washed with medium, and DRG neuron cells were uniformly plated onto plates with one of the following three surface coating conditions: (1) intact collagen, (2) cleaved collagen, and (3) cleaved collagen + CMP. The plates were then incubated at 37° C. for 48 hours, and then examined for morphology and neurite outgrowth by inverted bright-field microscopy. Representative results are shown in FIGS. 14 and 15.

[0525] Figure 14 shows that DRG neurons showed substantial neurite outgrowth in all directions from the cell body when plated on collagen-coated plates (Figure 14A), but reduced neurite outgrowth on plates coated with cleaved collagen (Figure 14B). However, the CMPs of the present invention were able to repair the collagen matrix on the plates to the extent that DRG neurons showed substantial neurite outgrowth well beyond that seen on cleaved collagen plates, and certain CMPs were found to induce neurite outgrowth similar to or greater than that seen with intact undigested collagen (Figures 14C-14F). Quantification of the area of ​​dendritic fields normalized to that observed on cleaved collagen plates (Figure 15A) showed that none of the CMPs tested was significantly different from that observed on intact collagen plates (p=0.15). Furthermore, as shown in FIG. 15B, the length of the longest neurite (normalized to sheared collagen) observed on plates treated with CMP C (SEQ ID NO: 391) and CMP D (SEQ ID NO: 13) was even greater than that observed with intact collagen (p≦0.002). These results correlate on a primary neuronal cell basis with the RPE cell results of Examples 2 and 3, which demonstrated the effect of CMP treatment on the remodeling of disrupted collagen matrix in vitro, and demonstrate that certain CMPs of the invention are useful in promoting neuronal cell proliferation, migration and network formation by enhancing the repair of disrupted collagen matrix. Taken together, these results suggest that the CMPs of the invention may prove useful in treating, ameliorating, preventing and diagnosing a variety of diseases and disorders involving nerve cells and the nervous system. EXAMPLES

[0526] Penetration of CMP from the ocular surface to the retina The inventors sought to further explore the potential therapeutic efficacy of the CMPs and CMP-TC conjugates of the present invention in ocular fundus conditions, particularly those conditions in which the collagen matrix may be disrupted. In treating certain such conditions, it is desirable to be able to instill a therapeutic composition onto the ocular surface rather than subjecting the patient to the more invasive procedure of intravitreal injection. Instillation of such therapeutic agents into the eye can be easily accomplished by the patient in their own home, rather than in a clinic as is required for intravitreal injections, thus enhancing patient comfort and compliance with the treatment. Thus, a study was designed to test the ability of certain CMPs to penetrate the cornea into the retina in an in vivo setting, i.e., in intact mouse eyes.

[0527] To test the ability of CMP to penetrate the ocular surface into the fundus, a CMP conjugated with a fluorophore was made. In these studies, a CMP having the amino acid sequence (Pro-Pro-Gly)7 (SEQ ID NO: 1) was conjugated at its C-terminus with Tide Fluor®2 (AAT Bioquest, Sunnyvale, Calif.) and obtained from Bachem (Torrance, Calif.). This fluorescent conjugate is referred to herein as "TF2-CMP." Female mice (8-week-old C57BL / 6) were anesthetized and TF2-CMP was administered to both eyes in the form of drops administered to the surface of the eye (bilateral, once daily for 3 days, 10 μL of 200 μM TF2-CMP solution in PBS per injection) or to the fundus by intravitreal injection as a positive control (bilateral, one injection only on the third day, using a pull-out glass needle for injection, 1.5 μL of 100 μM TF2-CMP solution in PBS per injection). Negative control mice were treated with vehicle (PBS) only. On the third day, the mice were sacrificed and the amount of fluorescence (representing the amount of TF2-CMP) in various parts of the eye structure was qualitatively examined by confocal fluorescence microscopy. The results are shown in FIG. 16.

[0528] As expected, intravitreal injection of TF2-CMP (FIGS. 16A and 16B) showed highly oriented binding of CMP to and near ganglion cell neurons in the ganglion cell layer of the retina (FIG. 16A), with numerous blood vessels (arrows) and ganglion cell nuclei (arrowheads) clearly visible in contrast. Fluorescence was found to be localized to the ganglion cell layer, and most of the TF2-CMP was not localized to the internal limiting membrane at the vitreous surface (FIG. 16B). Unexpectedly, similar results were observed in eyes of mice in which TF2-CMP was administered dropwise to the ocular surface for 3 days (FIGS. 16C and 16D). In these eyes, fluorescence was also oriented near ganglion cell neurons in the retinal ganglion cell layer (FIG. 16C), with numerous blood vessels (arrows) and ganglion cell nuclei (arrowheads) clearly visible in contrast. The amount of nonspecific fluorescence observed at the vitreous surface (FIG. 16D) was somewhat greater than that seen following intravitreal injection (FIG. 16B), suggesting that perhaps some of the TF2-CMP was retained within the internal limiting membrane at the vitreous surface or was in the process of crossing that membrane into the ganglion cell layer.

[0529] These results demonstrate that the CMP and CMP conjugates of the present invention can penetrate from the ocular surface through the cornea to the retina, more specifically through the internal limiting membrane of the retina to the ganglion cell layer. CMPs are also found to be present in the interstitial space and / or on the cell surface, and do not penetrate to the ganglion cell nucleus or through the basement membrane of the retinal blood vessels. Taken together, these results show that the instillation of the CMP and CMP conjugates of the present invention produces penetration results that are at least highly similar to those of direct intravitreal injection of the composition. These results support the conclusion that a more patient-friendly and patient-compliant approach to posterior ocular diseases and disorders may be achieved by instillation of the CMP and CMP conjugates of the present invention, rather than more invasive approaches such as intravitreal injection.

[0530] The present invention has been described above using functional building blocks that illustrate the implementation of certain functions and their relationships. The boundaries of these functional building blocks have been arbitrarily defined herein for convenience of description. Alternative boundaries can be defined so long as the certain functions and their relationships are appropriately performed. For example, a description of a range of values ​​(e.g., a range of dosages or concentrations) should be understood to include the first and last values ​​of the range, as well as every value between the first and last values. To illustrate this concept, the range "about 25 ng / ml to about 250 ng / ml" should be interpreted as including "about 25 ng / ml," "about 250 ng / ml," and every individual concentration value between those two values. The term "about" when used in conjunction with a numerical value typically means a value that is an actual value within ±10% of that value.

[0531] The above description of the specific embodiments fully reveals the overall nature of the present invention, so that by applying knowledge within the skill of the art, the embodiments can be easily modified and / or adapted for various applications without departing from the overall concept of the present invention and without undue experimentation. Therefore, based on the above description and examples and knowledge generally available in the art, those skilled in the art will easily understand other suitable embodiments of the present invention other than those specifically described herein. Therefore, such modifications and changes are intended to be included within the meaning and range of equivalents of the disclosed embodiments based on the teachings and explanations presented herein. It should be understood that the expressions or terms in this specification are intended to be interpreted by those skilled in the art in light of those teachings and explanations, since the expressions or terms in this specification are intended to be explanatory and not limiting.

[0532] The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.

[0533] All references cited herein, including U.S. patents and published patent applications, international patents and patent applications, and periodical references or other publicly available documents, are incorporated herein by reference in their entirety to the same extent as if each reference was specifically cited for the portion or portions of that reference that are applicable to the portion of this application to which it pertains.

Claims

1. 1. A pharmaceutical composition for treating a posterior ocular disease or disorder involving the retina, retinal vasculature, retinal nerve, or optic nerve in a human or veterinary subject in need of such treatment, comprising: (a) at least one collagen pseudopeptide (CMP) comprising the amino acid sequence of SEQ ID NO:6; and (b) one or more pharmacologic carriers.

2. The composition of claim 1, wherein the at least one CMP is linked to at least one therapeutic compound (TC) to form a CMP-TC conjugate.

3. The composition of claim 1 , wherein the posterior ocular disease or disorder involves the retinal epithelium.

4. 2. The composition of claim 1, wherein the posterior ocular disease or disorder is selected from the group consisting of macular degeneration, retinitis pigmentosa, retinal tear, retinal detachment, retinopathy, retinal artery or vein occlusion, optic neuritis, optic neuropathy, and optic nerve atrophy.

5. The composition of claim 4, wherein the macular degeneration is selected from wet macular degeneration, dry macular degeneration and age-related macular degeneration.

6. The composition of claim 4 , wherein the retinopathy is diabetic retinopathy.

7. A medical device for treating a posterior ocular disease, disorder or condition involving the retina, retinal vasculature, retinal nerve, or optic nerve in a human or veterinary subject suffering from or susceptible to said disease, disorder or condition, comprising: (a) at least one collagen mimetic peptide (CMP) comprising the amino acid sequence of SEQ ID NO:6; and (b) one or more pharmacologic suitable carriers.

8. 8. The medical device of claim 7, selected from the group consisting of a stent, a shunt, a suture, an absorbable mesh, an absorbable patch, a drug-releasing wafer, a film, and an internal infusion pump.

Images